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Abstract 
The highly regenerative nature of the human endometrium has caused much 
speculation over the existence of resident stem/progenitor cells (SPCs) within this 
tissue. Endometrial SPCs may be associated with a variety of gynaecological 
pathologies such as endometriosis. Although common, little is known about the 
pathogenesis of this condition and the lack of defining markers of putative 
endometrial SPCs makes the isolation and analysis of these cells difficult. The well 
characterised endometrial stromal stem cells are only able to regenerate a stromal 
cell population of the endometrium in 3D in vitro or animal xenograft models. This 
suggests that there is a separate endometrial epithelial SPC that gives rise to the 
endometrial epithelial cells, including the glands and the surface epithelium. SSEA-
1, a surface glycolipid expressed by embryonic stem cells (ESCs), has recently been 
identified as a possible endometrial epithelial progenitor cell marker by our lab. 
However, the gene expression profile of the SSEA-1
+
 endometrial epithelial cells has 
yet to be assessed. With the use of qPCR, we aimed to further characterise the SSEA-
1
+
 endometrial epithelial cell population by assessing their gene expression profile 
for common markers of stemness and an undifferentiated state when grown in both 
2D and 3D culture. As abnormal endometrial SPCs are speculated to be involved in 
the pathogenesis of endometriosis, we further investigated the gene profile of SSEA-
1 expressing endometrial epithelial cells in this condition. Within the normal 
endometrium, we found no differences between the levels of stem cell markers 
expressed by the SSEA-1
+
 and SSEA-1
-
 epithelial cell populations grown in 2D 
culture. Significant up-regulation of markers of differentiation, ERα and PR, within 
the SSEA-1
- 
cells confirmed the existence of a more differentiated cell state within 
this population. SSEA-1
+
 epithelial cells grown in 2D culture exhibited significantly 
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higher levels of stem cell marker expression in patients with endometriosis than 
those with a normal endometrium, confirming their association with this disease. 
When grown in 3D culture endometrial epithelial cells form gland-like structures 
also called spheroids/organoids, similar to those seen within the endometrium. 3D 
Matrigel culture mimics the endometrium and the stem cell niche in vivo and 
therefore acts as a better culture system to preserve stemness and accurately reflects 
in vivo physiology. Unlike the 2D culture, SSEA-1
+
 epithelial cells grown in 3D 
culture exhibited a clear up-regulation of markers of stemness when compared to the 
SSEA-1
-
 cell population, in both normal and endometriosis tissue. This difference 
was more pronounced in cells taken from women with endometriosis, again 
indicating its link with this condition. High levels of ERα and stable levels of PR 
expression indicated elements of oestrogen responsiveness and progesterone 
resistance within the 3D cultured SSEA-1
+
 epithelial cells taken from women with 
endometriosis, and are known features of endometriosis. These findings provide 
further evidence to suggest that endometrial epithelial SPCs are contained within the 
SSEA-1
+
 cell population displaying greater stem cell activity than the SSEA-1
- 
population, but only when grown in 3D culture which mimicks their in vivo 
environment. This highlighted the significance of the surrounding stem cell niche in 
preserving stemness and preventing differentiation. Furthermore, our study 
demonstrats that this sub-population of SSEA-1
+
 epithelial SPCs are in some way 
involved in the pathogenesis of endometriosis. 
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Chapter 1: Introduction 
The human endometrium is a highly dynamic tissue, undergoing over 400 cycles of 
shedding and regeneration throughout a female’s reproductive years. Due to its 
immense regenerative capacity, it has long been proposed that a putative adult stem 
cell (ASC) population must be driving its re-growth, yet it is only over the last 8 years 
since the first evidence emerged that research has been dedicated to the identification 
of such cells. The use of endometrial ASCs in regenerative medicine is an exciting 
prospect, acting as an easily accessible and renewable source. Endometrial ASCs are 
also said to be associated with the pathogenesis of a variety of gynaecological 
conditions such as endometriosis, about which little is known and treatment is still 
limited. As a result of previous studies, it is now established that two distinct stem cell 
populations give rise to the two main cell types of the endometrium, the stroma and the 
epithelium. To date, most research has focused on the stromal stem cell due to their 
ease of culture, yet very little is known about the epithelial cell population. It is 
therefore the main focus of this study, to help identify and characterise a putative 
epithelial stem/progenitor cell (SPC) within the endometrium. Before beginning this 
study, a thorough literature review of the scientific advances within this field had to be 
conducted. 
 
1.1 Structure of the Human Uterus and Endometrium 
The female reproductive system can be divided into two sections: the lower and the 
upper genital tracts. The lower genital tract consists of the vagina and vulva, whereas 
the upper portion is made up of the anatomical structures known as the uterus and 
cervix, along with the attached fallopian tubes and ovaries. The uterus is a thick, 
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muscular organ situated in the midline of the pelvic cavity between the urinary bladder 
and rectum (Sandring, 2008). It acts as the body of the genital tract, and is vital for 
hosting a pregnancy following the fertilisation of an ovum after its release from the 
ovaries and migration through the fallopian tubes. (Aplin, 2008). The uterus measures 
7.5 cm in length and sits in an anterior-posterior position with its apex directed 
downwards and backward (Gray’s 
Anatomy of the Human Body, 2012). 
The uterine body forms the upper 
two-thirds and tapers down to form a 
narrow neck known as the cervix, 
which in turn sits at the superior part 
of the vagina. The uppermost part of 
the body is named the fundus. Although the morphology of the uterus varies amongst 
females of different species, its basic structure is common to all mammals (Aplin, 
2008). The structure of the uterus is illustrated in the diagram shown (figure 
1.1)(NUFF, 2012).  
 
    
The uterine mucosa, also known as the endometrium, is the innermost layer lining the 
uterine cavity and plays an essential role in fetal development (Aplin, 2008). It is a 
highly dynamic and regenerative tissue found on the thick smooth muscle of the 
myometrium. These two tissue types meet at the irregular endometrial-myometrial 
junction with no submucosal tissue to separate them. Embryologically the 
endometrium and subendometrium are said to originate from the two paramesonephric 
ducts known as the Műllerian ducts, unlike the outer myometrium which later develops 
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during fetal life (Gargett, 2007). Microscopically the human endometrium is composed 
of two main cell types: the epithelial cells which line the lumen and glands, and the 
supporting stromal or mesenchymal cells. Other cell types found within the 
endometrium include endothelial cells and leukocytes. The endometrium is divided 
into two separate layers, the functionalis and the basalis, based on their structural and 
functional differences. The functionalis layer, the upper two-thirds of the 
endometrium, is composed of dense glandular tissue surrounded by a loose connective 
stroma (Figueria et al, 2011). Its role is to accommodate 
an implanting blastocyst, and also to provide the 
maternal element of the placenta (Aplin, 2008). It is this 
layer which is lost during menses. On the contrary, the 
lower basalis is maintained following each menstrual 
cycle, and is known to contain the gland bases, dense 
stroma and large vessels. It is therefore thought that this 
basalis layer is responsible for the generation of a new 
functionalis each month and is where the endometrial 
SPCs must reside (Figueria et al, 2011). The histology 
of the human endometrium is shown in figure 1.2 
(Gargett, 2007). 
 
1.2 The Human Menstrual and Ovarian Cycles 
The uterus and its endometrial lining play an essential role in the key events of primate 
reproduction, implantation and when in the absence of pregnancy, menstruation 
(Critchley et al, 2006). During a woman’s reproductive years, the endometrium 
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undergoes over 400 cycles of monthly regeneration, differentiation and shedding in 
response to hormonal changes that occur within the body (Gargett et al, 2010). This 
dynamic remodelling and cyclical change ultimately occurs to provide the optimal 
environment for embryo implantation and is tightly controlled by endocrine, autocrine 
and paracrine factors that not only influence the endometrium, but follicle maturation 
and ovulation also. The transformation of the endometrium throughout the cycle comes 
with classical morphological and histological changes, which allow for dating the 
cycle with the use of endometrial biopsies. It is important to note that whilst many of 
the fundamental reproductive processes are common between different mammalian 
species, the mechanism for implantation varies widely and therefore to complement 
this endometrial preparation and remodelling differ also (Aplin, 2008; Mihm et al, 
2011). 
 
1.2.1 The Human Menstrual Cycle 
Women first start menstruating during the final stage of puberty, also known as 
menarche, commonly between the ages of 8.5 to 13 years. A woman’s reproductive 
years span around 36 years, ending when she reaches the menopause around the age of 
51 (Mihm, 2011). For most women, the standard cycle length is 28 days, although this 
commonly fluctuates between 26 to 32 days. The new cycle begins with the first day of 
menstrual bleeding, with ovulation occurring mid-cycle around day 14.The menstrual 
cycle in all women can be described by dividing it into three phases; menstrual, 
proliferative (or follicular) and secretory (or luteal). Broadly speaking, menses 
encompasses the breakdown of the functional endometrium, although simultaneous re-
epithelialisation is also initiated during this phase. Following this, there is rapid 
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cellular proliferation and generation of a new extracellular matrix (ECM) in response 
to the secretion of oestrogen; hence this phase is named the proliferative phase (Aplin, 
2008). During the process of endometrial regeneration, the mucosal tissue can grow up 
to 8mm in thickness (Kyo et al, 2011). Following ovulation, within the secretory phase 
of the cycle progesterone stimulates functional differentiation of the endometrium in 
preparation for implantation. Endometrial glands become increasingly active and more 
tortuous and following day 22 stromal differentiation and endometrial dicidualisation 
favour successful implantation and placentation. This short period of heightened 
uterine receptivity towards embryo implantation within this phase is named the 
‘window of implantation’. If fertilisation does not occur, hormone levels subsequently 
fall, the endometrium begins to regress and the cycle starts over again (Aplin, 2008; 
Buffet et al, 1998). A schematic of the human menstrual cycle is illustrated in figure 
1.3 (Gargett et al, 2008).  
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Menses 
If implantation and pregnancy do not occur, a demise of the corpus luteum leads to the 
rapid drop in levels of the ovarian steroid hormones, progesterone and oestrogen, and 
initiates endometrial breakdown between days 1 to 4 of the cycle. Spiral arteries within 
the functionalis undergo repetitive constriction and relaxation, eventually leading to a 
loss of vascular integrity. Bleeding into the stromal compartment of the endometrium 
causes cleavage between the basal and functional layers, the latter of which is 
completely lost during menstruation. This eventually leads to tissue apoptosis and 
necrosis, a loss of cellular adhesion and cell membrane actin, and the breakdown of the 
glandular epithelium. In addition, endothelial injury promotes the release of 
inflammatory mediators such as prostaglandin F2α and E2, platelet aggregation and the 
formation of thrombin within the basal layer. Rising levels of prostaglandins in turn 
stimulate myometrial contractility and vasoconstriction of the spiral arteries. Local 
responses are mediated by leucocytes which secrete matrix metalloproteases (MMPs). 
These MMPs cause direct destruction of the cellular membranes and a loss of the 
ECM. Towards the end of menses, on day 3, haemostasis occurs within the basal layer 
and surface re-epithelialisation and regeneration occurs under the control of oestradiol, 
originating from the glandular stumps.  Menstrual bleeding is an external manifestation 
of the internal physiological processes which occur during menses, with the heaviest 
flow usually noticed at day 2 (Aplin, 2008; Mihm et al, 2011).   
 
Proliferative Phase 
The proliferative phase occurs between days 5 to 14, up to the time of ovulation. Under 
the influence of oestrogen, throughout this phase there is extensive growth and re-
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epithelialisation of the endometrium and it increases in thickness from 1mm up to 3-
4mm. Early repair of the endometrium occurs whilst oestrogen levels are low and 
epithelial cells do not express oestrogen receptor α (ERα). During this stage, oestrogen 
levels rise and both the epithelial and stromal cells gain the surface receptors ERα and 
progesterone receptor (PR). Under the control of these hormones, throughout days 5-7 
(early proliferative phase) the functionalis is regenerated and there is vast proliferation 
of the glandular epithelium and to a lesser degree, the stroma. Histologically the 
cellular morphology changes throughout the proliferative phase. Within the early 
proliferative phase (days 5-7), endometrial glands are undifferentiated and straight in 
appearance. Under cross section the glands look circular and are seen to be lined with 
columnar epithelial cells containing nuclei near the basal surfaces. The glandular 
epithelium stays relatively constant in size throughout this period, and occasionally 
cells can be seen undergoing mitosis.  Stromal cells appear spindle-like in shape and 
contain large nuclei. As this phase progresses to between days 8 and 10 (mid-
proliferative phase), the endometrial glands appear taller and more tortuous. Towards 
days 11 to 14 (late proliferative phase), the glands becomes increasingly 
pseudostratified and tortuous in morphology. Mitotic figures become more pronounced 
and stromal oedema becomes apparent (Aplin, 2008; Gargett et al, 2008).  
 
Secretory Phase 
After ovulation at day 14, the secretory phase begins and extends up to day 28. This 
part of the menstrual cycle is commonly separated in to three parts: the early, mid and 
late secretory phases. It is during this phase that all endometrial cell types undergo 
function differentiation, priming the endometrium for the implantation of an embryo. 
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Proliferation is suppressed and under the influence of progesterone produced by the 
corpus luteum, differentiation begins. As the name suggests, the endometrium 
produces large amounts of secretions during this phase, named histotroph. Although 
the exact composition of these secretions is still unknown, it is said to contain transport 
proteins, glucose, hormones, growth factors and enzymes in addition to other 
substances. In order to prepare for blastocyst implantation, the glandular epithelia 
begin to secrete large amounts of glycogen and histotrophic secretory products under 
the influence of progesterone. Progesterone also triggers the influx of specialised 
uterine natural killer (uNK) cells as a response to the release of local chemokines. uNK 
cells are an important source of both growth and angiogenic factors, and they enable 
spiral artery remodelling required in preparation for a pregnancy. During the majority 
of the menstrual cycle, the endometrium is named as either ‘hostile’ or ‘non-receptive’ 
to an incoming blastocyst, except for a short period during the mid-secretory phase 
named the ‘window of receptivity/implantation’. Progesterone inhibits the action of 
ERα and epithelial PR within the functionalis, although they remain functional within 
the basalis. Within the stromal compartment of the functional layer, PR remains active 
and these cells differentiate and undergo pre-decidual changes. In response to this 
postovulatory increase in progesterone, endometrial stromal cells are seen to change 
greatly in morphology, forming secretory epithelioid-like decidual cells (Aplin, 2008; 
Gargett et al, 2008; Gellerson et al, 2007).  
 
1.2.2 The Ovarian Cycle 
Synchronised with the cyclical changes of the endometrium, the ovaries go through 
their own physiological changes. Analogous to the male testes, the ovaries are the 
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reproductive organs within females and act as both gonads and endocrine glands. 
Under the influence of the hypothalamo-pituitary-ovarian (HPO) axis, the ovaries 
control follicular maturation in the aim to produce one mature oocyte each month. 
Gonadotrophin-releasing hormone (GnRH) is released from the hypothalamus in a 
pulsatile manner which in turn stimulates the pituitary gland to secrete luteinising 
hormone (LH) and follicle-stimulating hormone (FSH). The ovaries respond to the 
release of FSH and LH in a cyclical manner called the ovarian cycle and in turn secrete 
the ovarian hormones oestrogen and progesterone (Buffet et al, 1998; Sadler et al, 
2006). Primordial germ cells (PGSs) are diploid precursors of female and male 
gametes. In order to develop into an egg ready for ovulation, it must pass through 
several stages of maturation through a process called oogenesis. PGSs arise in a 
developing embryo at around 3 weeks post-fertilisation. These exist only transiently 
during which they multiply and migrate to the genital ridge, where they are then named 
oogonia. The population of oogonia continue to proliferate and expand via mitosis 
until they stop and enter meiosis. At this point they are now called primary oocytes. 
Primary oocytes remain arrested in prophase I of meiosis until the female reaches 
sexual maturity during puberty. The ovaries of a female embryo contain 7 million 
oocytes in utero. Of these, only around 400 ovulate and the remainder undergo atresia. 
The next stage in oocyte development continues when meiosis is resumed in 
preparation for ovulation. It then forms a secondary oocyte and in addition releases the 
first polar body. The secondary oocyte is arrested at meiosis II until fertilisation occurs 
and a haploid gamete is produced.  
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Primordial follicles are the basic functional units of the ovary and contain the 
developing oocyte. Like the ooctye, an ovarian follicle must also grow and mature 
before ovulation can occur, in a process called folliculogenesis. Entry of the oogonia 
into meiosis I initiates the development of the primordial follicle. As this primordial 
follicle grows it must pass through a series of stages through which it becomes a 
primary follicle, a secondary follicle and finally a tertiary or pre-ovulatory follicle. A 
primordial follicle is made up of a primary oocyte surrounded by a layer of flattened 
granulosa cells. During the development of primary follicles into tertiary follicles, the 
granulosa cells proliferate and undergo changes from a flattened to a cuboidal 
epithelial morphology. Eventually this process gives rise to a follicle with multiple 
granulosa cell layers surrounded by an outer layer consisting of thecal cells and a 
basement membrane (Smitz et al, 2002; Mtango et al, 2008). 
 
Like the menstrual cycle, the ovarian cycle too lasts 28 days. It is split into two phases, 
the follicular and luteal phase, each lasting 14 days (Buffet et al, 1998).  
 
Follicular Phase 
At puberty, the levels of circulating FSH rise and a cohort of mature follicles are 
selected for initial recruitment. From these, a single dominant follicle is chosen. It 
takes 150 days for a primordial follicle to mature into a primary follicle and a further 
120 days to develop into a secondary follicle. This means that it takes the equivalent of 
9 menstrual cycles until a follicle can become part of a selectable cohort. The 15 days 
following this is the time taken for a selected follicle to become a dominant and 
equates to the period of the follicular phase. Nearing the end of the menstrual cycle, if 
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a pregnancy is not achieved, the corpus luteum starts to regress and the levels of 
oestrogen and progesterone begin to fall. These decreasing hormone levels stimulate 
the anterior pituitary gland to increase the secretion of FSH, which in turn stimulates a 
cohort of follicles to grow. Of these, one follicle will grow at the faster rate than the 
others and will secrete higher levels of oestradiol (E2) and inibin-B. These hormones, 
produced by the dominant follicle, have a negative effect on the pituitary and cause 
suppression of FSH secretion around the mid-follicular phase.  This withdrawal of 
FSH results in apoptosis of the remaining non-dominant follicles. FSH activates LH 
receptors within the theca cells of the dominant follicle and in turn stimulates its 
production of E2. E2 has a stimulatory effect on FSH and LH which surge around day 
14 and result in the meiotic maturation of the oocyte and follicular rupture to release 
the ovum in a process known as ovulation. The tissue that remains behind forms a 
body known as the corpus luteum (Tulsiani, 2003).  
 
Luteal Phase 
The surge of LH around the time of ovulation causes the corpus luteum to become 
leutinised and synthesise oestrogen and more importantly progesterone. The corpus 
luteum stays functional for a period of 14 days, under the control of LH. In the absence 
of a pregnancy, the corpus luteum begins to degenerate and is replaced by connective 
tissue termed the corpus albicans. In the event that fertilisation does occur, the 
developing blastocyst secretes human chorionic gonadotrophin (hCG) which prevents 
breakdown of the corpus luteum. During the final 4-5 days of the cycle plasma levels 
of oestrogen and progesterone decline rapidly, previous suppression of GnRH and FSH 
is removed and the cycle repeats itself (Tulsiani, 2003).  
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1.3 Stem Cells 
1.3.1 Definition of Stem Cells 
Stem cell biology and its application in future regenerative medicine, is currently one 
of the most exciting and continually expanding areas of biomedical research (Sylvester 
et al, 2004). The concept of a stem cell is difficult to define and has been the cause of 
much controversy over the years. Their lack of morphological features makes them 
difficult to identify and locate within tissues, and so alternatively they are described by 
their characteristic functional properties (Potten et al, 1990; McCullock et al, 2005). 
Within the literature, stem cells are commonly defined as a rare population of 
undifferentiated cells which are able to divide in order to maintain their pool within the 
tissue and also to give rise to specialised tissue-specific cells with defined functions. In 
order for a cell to possess the characteristics of a stem cell, it must possess three 
functional properties: a high proliferation potential, the ability to self renew and the 
capacity to differentiate (Gargett, 2007). The proliferation potential of a cell is 
determined by calculating the number of times a cell population doubles from the 
existence of a single cell until senescence (Gargett, 2007; Cervello et al, 2011). Self 
renewal is known as the ability of a cell to divide producing an identical daughter cell, 
ultimately allowing it to retain its population within the tissue (Bach et al, 2000). 
Differentiation on the other hand is defined as the change of cell phenotype based on 
gene expression associated with cell function rather than cell division (Figueira et al, 
2011).  
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1.3.2 Stem Cell Hierarchy 
Stem cells display a varying ability to differentiate, depending on their position within 
the hierarchy of stem cells. This is illustrated in figure 1.4 (Kyo et al, 2011).  
 
 
‘Totipotent’ stem cells, such as the zygote, are fully undifferentiated cells positioned at 
the top of this hierarchy. These have the ability to produce cells of all three embryonic 
germ layers (endoderm, mesoderm and ectoderm), in addition to cells derived from 
extra-embryonic tissues (these being the trophoblast, placenta and extra-embryonic 
membranes) (Figueira et al, 2011). Next in line are embryonic stem cells (ESCs), 
derived from the inner cell mass of the blastocyst. These are named ‘pluripotent’ as 
they can give rise to an embryo, and were first isolated in mice in the year 1981 and in 
humans in the late 1990s. They are not able to produce extra-embryonic tissues (Kyo et 
al, 2011; Eckfeldt et al, 2005). As embryonic development continues, the 
differentiation potential of these cells becomes ever more restricted. ASCs, also 
referred to as somatic stem cells (SSCs), arise from these and are found in most adult 
16 
 
tissues. They can be classified as either ‘multipotent’ or ‘unipotent’, dependent on 
whether they can produce multiple cell types in a germ cell lineage or into only one 
cell type within that lineage respectively (Figueira et al, 2011; Kyo et al, 2011; Aplin, 
2008).  
 
ASCs in different tissues, such as haematopoietic, neural, epidermal and even 
gastrointestinal stem cells, have now been identified. They act to maintain tissue 
homeostasis by generating and regenerating adult tissue during the processes of normal 
physiological cell turnover and in the event that tissue damage may occur. However 
they exhibit a much lower self-renewal capacity when compared to that of ESCs 
(Eckfeldt et al, 2005; Gargett et al, 2010). To date, the best described ASCs are those 
derived from the bone marrow, including haematopoietic and mesenchymal (or 
stromal) stem cells (MSCs) (Cervello et al, 2011). The particular topic surrounding 
ASC plasticity and therefore the fate of ASCs, has caused much controversy within the 
literature. Contrary to common belief, it is now suggested that ASC can undergo 
transdifferentiation or plasticity, in which the cells can be converted from one cell 
lineage to another as a result of a change in the extracellular environment. This 
property has been described within the stem cells of the bone marrow. They are seen to 
travel within the blood stream and are eventually incorporated for use in the 
regeneration of damaged tissues such as muscle, the brain, heart or the liver. The 
implications of such research findings are important as it may imply that ASCs are 
more similar to ESCs than originally thought, and could have alternative therapeutic 
uses. Due to the rarity of stem cell plasticity however, this concept if often rejected and 
alternative explanations given (Gargett, 2007; Wagers et al, 2004). 
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1.3.3 Stem Cell Division 
Stem cells demonstrate two different 
mechanisms of cellular division which 
enable the stem cell pool to be 
maintained. These are named 
asymmetric and symmetric cell division. 
Asymmetric division (shown in figure 
1.5 (Gargett, 2007)) is demonstrated 
when a stem cell produces an identical 
daughter cell, thereby exhibiting the property of self-renewal. Simultaneously a more 
differentiated cell, also known as a progenitor cell is produced (Aplin, 2008). 
Progenitor cells are tissue-specific cells which are set on a particular path of 
differentiation and therefore only have a limited ability to self-renewal. These 
progenitor cells in turn give rise to transient amplifying (TA) cells, which have 
properties mid-way between stem cells and fully differentiated mature cells. TA cells 
proliferate rapidly, progressively gaining in differentiation markers and eventually 
produce terminally differentiated cells (Gargett, 2007; Kyo et al, 2011). In contrast, a 
stem cell may alternatively choose to undergo symmetric cell division, producing 
either two daughter stem cells, or two TA progenitor cells (Aplin, 2008).  
 
1.3.4 The Stem Cell Niche 
Stem cells reside within and are regulated by a special physiological microenvironment 
that is tailored to its needs, as first described by Schofield in 1978. This is commonly 
referred to as the stem cell niche (Schofield, 1978). The structure and location of the 
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stem cell niche is variable depending on the resident tissue. Much of what is known 
about the stem cell niche has been discovered due to the work on other organisms, 
such as the Drosophila melanogastor and Caenorhabditis elegans gonads. Although 
less is known in comparison about the more complex mammalian stem cell niches, 
similarities can be drawn between the two (Ohlstein et al, 2004). ASCs are found to 
have a precise location within the niche, and are surrounded by mature, fully 
differentiated cells in an ECM. Adhesion molecules, such as cadherins and integrins, 
and the surrounding niche cells aid in anchoring the ASCs during periods of inactivity 
and manage the controlled release of daughter cells from this micro-environment 
following asymmetrical cell division. The essential function of this niche is to regulate 
signals controlling the balance between ASC self renewal for tissue replacement and 
cell differentiation, thereby preserving homeostasis within the tissue (Gargett, 2007; 
Cervello et al, 2011; Li et al, 2005). 
 
1.4 Stem Cells and the Endometrium 
As previously discussed, the endometrium is a highly dynamic and regenerative tissue 
undergoing monthly cycles of shedding and regeneration throughout a woman’s 
reproductive years. In addition to this cyclical renewal, physiological regeneration is 
observed within the endometrium following childbirth, post-ablative therapy, post-
curettage and also within postmenopausal women given oestrogen replacement therapy 
(Gargett CE, 2008). This high cellular turnover is comparative with other organs in 
which a high turnover rate is also required, including the haematopoietic system, the 
epidermis and the intestinal epithelium in which stem cells have also been located 
(Cervello et al, 2011; Aplin, 2008). It is this combination of reasons that has caused 
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many to believe that stem cells may be responsible for endometrial regeneration. It was 
first postulated in 1978 by Prianishnikov and later by Padykula in 1984, that stem cells 
located within the basalis may be the drive behind the endometrium’s impressive 
regenerative capacity (Prianishnikov, 1978; Padykula et al, 1984).  
 
1.4.1 Human Endometrial Stem/Progenitor Cells: The Evidence 
Indirect Evidence 
Indirect evidence for the presence of endometrial ASCs has gathered over the years. 
Early kinetic studies investigating endometrial cell proliferation showed zonal 
differences determining the orderly replacement of the endometrial epithelial and 
stromal cells from rarely proliferating SPCs within the basalis (Ferenczy et al, 1979; 
Conti et al, 1984; Padykula et al, 1989). Later in 2003, Brenner et al observed a 
difference in the proliferative index between the glands of the functionalis and basalis 
layers, across both the proliferative and secretory stages of the menstrual cycle 
(Brenner et al, 2003). In 2005 endometrial epithelial stem cell kinetics were explored, 
by investigating epigenetic errors that had been encoded into particular methylation 
patterns of individual endometrial glands. The purpose was to determine the total 
number of stem cell divisions by calculating the number of somatic errors that would 
accumulate within a gland. An age-related increase in methylation was found up until 
the menopause, when methylation became constant, and therefore was seen as a 
reflection of stem cell mitosis (Kim et al, 2005). More recently, evidence emerged 
reporting the monoclonality of the endometrial glands, as proof that they arise from a 
single SPC. Within the normal proliferative endometrium, a rare population of glands 
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found unable to express phosphatase and tensin (PTEN null glands), are seen to 
regenerate their mutant glands with each cycle (Mutter et al, 2000).  
 
These indirect findings have also been supported by various clinical observations 
suggesting further evidence to pursue the stem cell hypothesis. Complete endometrial 
regeneration which is able to support a pregnancy following almost complete resection 
by curettage, has been seen in the clinical setting and also in primate studies (Hartman, 
1993; Wood et al,1993). In addition, this regeneration can be seen within the 
endometrium of women treated for menorrhagia with electrosurgical ablative therapy 
(Tresserra et al, 1999). The endometrium’s incredible ability to undergo ossification 
following trauma, such as a termination of a pregnancy, is said to be due to the 
incorporation of MSCs into the regenerating tissue (Biervliet et al, 2004; van Os et al, 
2004). Other tissue types such as smooth muscle, bone and cartilage have also been 
found in the uterine lining and suggest an ability to differentiate (Bird et al, 1965; Roth 
et al, 1966; Mazur et al, 1980).  
 
Evidence from Human Studies 
Although many had suspected the existence of resident SPCs within the endometrium 
for some time, it was only until much more recently that direct evidence based on 
functional assays was published.  In 2004, Chan et al used the concept of cell cloning 
to demonstrate the presence of separate epithelial and stromal stem cells in the human 
endometrium. Following single cell suspensions, 0.22 ± 0.07% and 1.25 ± 0.18% of 
epithelial and stromal cells formed individual colonies after 15 days, with large and 
small colonies formed from both cell types. Chan et al postulated that the large 
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colonies were formed from the resident SPCs with a greater ability to self-renew, 
whereas the small colonies were probably initiated by TA cells (Chan et al, 2004). In 
2005, Schwab et al provided further evidence that the proportions of clonogenic 
epithelial and stromal cells do not change across the stages of the menstrual cycle or in 
the inactive endometrium, supporting the hypothesis that putative endometrial SPCs 
must be located within the basalis (Schwab et al, 2005) (see figure 1.6 (Gargett, 
2007)).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stem cell subpopulations have been identified and analysed within previous studies 
using the ‘side-population’ approach, which is universally recognised as a marker of 
ASC activity (Challen et al, 2006). Side population (SP) cells, are a small number of 
cells which have the ability to efflux the fluorescent DNA-binding dye Hoechst 33342 
more rapidly, when compared to other cell populations. This occurs because SP cells 
are said to have an increased level of ABCG2/Bcrp I expression, an ATP-binding 
plasma membrane transporter protein, allowing the characteristic SP phenotype to be 
detected using flow cytometry (FC) (Kyo et al, 2011; Gargett et al, 2007). Several 
studies have all demonstrated the presence of SP cells within freshly isolated and also 
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short term cultures of human endometrial cells (Tsuji et al, 2008; Cervello et al, 2009; 
Masuda et al, 2010; Kato et al, 2007). Kato et al found that the percentage of SP cells 
varied greatly between subjects, from 0 to 5.11%. SP cells have been found in highest 
proportion within the proliferative and menstrual stages on the menstrual cycle (Kato 
et al, 2007; Tsuji et al, 2008). The majority of the SP cells sorted from short-term 
cultures were found to be negative for both endometrial epithelial (CD9) and stromal 
(CD13) cell differentiation markers, however in long term Matrigel culture the 
aggregates demonstrated the capacity to form CD9
+
E-cadherin
+
 gland like-structures 
and also CD13
+
 stromal-like clusters (Kato et al, 2007). SP cells cultured on feeder 
cells, showed slow proliferation and a colony forming ability comparable with the 
characteristics of SPCs, and were kept alive for over 9 months. This contrasts with the 
non-SP cells which became senescent following only 3 months (Masuda et al, 2010). 
 
Studies exploring the important functional stem cell property of differentiation and 
multi-potency have emerged recently within the human endometrium, however so far 
this has only been investigated within the endometrial stromal cell population. It has 
been documented that a subset of these stromal cells, taken from women within their 
reproductive years, could differentiate into adipogenic, osteogenic, myogenic and 
chondrogenic mesodermal cell lineages when cultured in the appropriate induction 
media (Schwab et al, 2007; Gargett et al, 2009; Dimitrov et al, 2008). Wolf et al 
demonstrated that amongst tissue biopsies taken from the endometrium, myometrium, 
fallopian tubes and uterosacral ligament, only cells taken from the endometrium were 
able to undergo chondrogenic differentiation following 21 days of culture (Wolf et al, 
2010). In the same study that proved epithelial cell clonogenicity, Gargett et al 
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continued to demonstrate that these same cells form spheroid structures positive for the 
epithelial marker cytokeratin in 3D Matrigel culture (Gargett et al, 2009). Kato et al 
also confirmed these findings by showing that epithelial SP cells aggregate into gland-
like structures in  Matrigel, expressing the epithelial markers CD9 and E-cadherin 
following 5 months of culture. Stromal SP cells did not behave in the same way (Kato 
et al, 2007).  
 
Although evidence is available to propose the differentiation ability of the 
endometrium, in vivo studies by Masuda et al and Cervello et al suggest otherwise. If 
an ASC is multi-potent and therefore has the ability to differentiate, in theory it should 
be able to adapt when placed in a different environment, giving rise to cells of the new 
tissue type (provided that the tissue has the same embryological origin). The kidney, 
like the endometrium originates from the intermediate mesoderm. However, when 
transplanted under the kidney capsule of immunocompromised mice, endometrial SP 
cells (epithelial and stromal mix) and pure stromal SP cells gave rise to endometrial 
tissue containing glandular and stromal structures at the site of transplantation. This 
raises some question as to the endometriums ability to differentiate (Masuda et al, 
2010; Cervello et al, 2010).  
 
Evidence from Mouse Studies 
The label-retaining cell (LRC) technique, like the SP phenotype, is another method 
used to identify and locate adult endometrial stem cells within the niche (Chan et al, 
2006; Cervello et al, 2007; Szotek et al, 2007; Kaitu’u-Lino et al, 2010). Unfortunately 
due to the nature of this technique however, LRCs cannot be used in humans. 
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Although mice do not menstruate, but rather undergo cycles of proliferation and 
apoptosis, the mouse is still a well established animal model used to investigate the 
human endometrium due to its structural similarity (Aplin, 2008). The LRC approach 
uses the thymidine analogue, 5-bromo-2-deoxyuridine (BrdU), which once 
administered is taken up by the DNA of growing cells and therefore is commonly used 
for cell proliferation assays. Once labelled and the cells begin to divide, the label gets 
diluted and over time is eventually lost. Based on the principle that SPCs are slowly 
dividing and quiescent in nature, they retain the BrdU label over a long period of time 
and therefore can be detected even following many cell divisions (Kyo et al, 2011; 
Gargett CE et al, 2007). 6-9% of stromal cells, mainly located next to blood vessels 
near the endometrial-myometrial junction, were found to be LRCs. This corresponds to 
the hypothesised basal location of the SPCs within the endometrium (Chan et al, 2006; 
Cervello et al, 2007). Epithelial LRCs were found in 3% of the mouse endometrial 
epithelial cell population, and were seen within the luminal epithelium rather than the 
basal glands. This could be explained by the fact that unlike humans, mouse 
endometrium is not lost through menstruation, and so may in fact be where the SPCs 
reside in mice (Chan et al, 2006). Another study by Kaitu’u-Lino et al used the LRC 
technique on a mouse model mimicking the events of the human menstrual cycle. They 
identified that glandular epithelial cells were highly proliferative during the period of 
endometrial repair, but not before breakdown, as opposed to luminal epithelial cells 
which proliferated throughout both. The majority of the glandular epithelial LRCs 
were also found to be ERα positive during the time of repair. These findings suggest 
that only the glandular epithelium selectively proliferates during endometrial repair, in 
response to oestrogen. In addition, 7% of glandular epithelial LRCs were ERα negative 
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even throughout repair, and so may have located SPCs based on the theory that stem 
cells should remain in an undifferentiated state and therefore would be ERα negative 
(Kyo et al, 2011; Kaitu’u-Lino et al, 2010). 
 
1.4.2 The Origin of Endometrial Stem/Progenitor Cells 
Initially it was first postulated that foetal epithelial and MSCs persist in the adult uterus 
following embryonic development, and are responsible for the replenishment of the 
functional layer of the endometrium during each menstrual cycle (Snyder et al, 2005). 
Studies have now shown however, that there may also be an additional bone marrow-
derived element. It is possible that bone marrow-derived stem cells (BMDCs), which 
have the capability of differentiating into both haematopoietic and MSCs, may migrate 
to damaged tissues such as the endometrium. They may transdifferentiate into cells of 
the damaged tissue and may also contribute to angiogenesis, allowing repair (Figueira 
et al, 2011). In 2004, Taylor et al performed reverse transcriptase-polymerase chain 
reaction (RT-PCR) and immunohistochemistry (IHC) on the endometrial biopsies of 
four women who received HLA-mistmatched bone marrow transplants from other 
female donors. The results showed 0.2-48% of chimerism in the epithelial cells and 
0.3-52% in the stroma across the transplant recipients, indicating that BMDCs must 
have been involved in the re-growth of the endometrium. The extent of chimerism 
seemed to correlate with the length of time elapsed since the time of transplantation 
(Figueira et al, 2011; Kyo et al, 2011; Taylor, 2004). As further evidence, a follow-up 
study was conducted in mice, in which female recipients received bone marrow cells 
from male donors. 0.02% of endometrial glands and 0.03% of stromal cells were 
shown to be Y chromosome-positive with fluorescence in situ hybridisation (FISH) 
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analysis (Du et al, 2007). A similar human study by Ikoma et al using sex-mismatched 
donors, revealed that 0.6-48% of glandular epithelial cells and 8.2-9.8% of stromal 
cells were Y chromosome-positive on FISH analysis (Ikoma et al, 2009).  
 
Although this evidence suggests that there must be a BMDC component to the 
regeneration of the endometrium, many unanswered questions still remain. More 
research needs to be undertaken to explore whether BMDCs normally migrate to the 
endometrium with each cycle, or whether this only occurs during transplantation. In 
addition, further research needs to investigate which type of BMDC is responsible for 
this (Gargett, 2007; Kyo et al, 2011).  
  
1.5 The Identification and Characterisation of Endometrial SPCs 
1.5.1 Stem Cell Markers 
Due to the lack of specific surface markers and the general scarcity of ASCs within 
tissues, the identification and characterisation of these SPCs is often found difficult. 
Instead ASCs have been investigated in the literature by using stem cell assays, to 
explore the aforementioned key functional properties that a stem cell should possess. 
Haematopoeitic stem cells (HSCs) are the best characterised ASCs. In comparison to 
other ASCs, HSCs are relatively easy to analyse due to their non-adherent and isolated 
existence within the bloodstream. Therefore it is not surprising that these cells initially 
served as a model for stem-cell biology and that it was on these cells that in vitro and 
in vivo functional assays were first developed. Although many have adapted these 
surrogate assays to investigate stem cells within other tissues, it is proving difficult 
when attempting to apply them to adherent cells that are likely to behave differently 
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when taken out of their natural microenvironment, in this case the endometrium. A lot 
of research has been devoted to the identification of stem cell markers within somatic 
tissue. The detection of such markers would allow the prospective isolation of stem 
cells in order to enable further characterisation, localisation within the tissue and also 
their use within medical therapies. Studies evaluating potential markers need to ensure 
that these marker expressing cells also display the functional properties of SPCs, as 
many markers currently used are also found on mature cells and therefore their 
expression does not necessarily imply stem cell activity. CD34 for example is classed 
as a HSC marker, however it is also found of the surface of mature endothelial cells. 
Another difficulty with surface markers, is that cells change their phenotype in culture 
and therefore the marker expression profile in vitro may not represent the markers 
expressed when in vivo (Aplin, 2008).  
 
1.5.2 Stem Cell Markers and the Endometrium 
There are currently no specific surface markers for endometrial epithelial SPCs that 
allow them to be distinguished from their mature progeny, and therefore would enable 
their prospective isolation for further characterisation (Aplin, 2008). The discovery of 
a specific endometrial epithelial and stromal SPC marker has been the target of many 
studies, as this is fundamental for the characterisation of undifferentiated stem cells. 
Although certain markers have been shown to be expressed within the endometrium, 
none have been proven to be cellular specific to the epithelial stem cell population 
(Oliveiria et al, 2012).  
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Endometrial stromal stem cells have recently been characterised by the co-expression 
of two peri-vascular markers, CD146 and PDGF-receptor-β (PDGF-Rβ) and also the 
novel single marker W5C5 (Gargett CE, 2009; Masuda H, 2012). The CD146
+
PDGF-
Rβ+ sorted stromal cells were found to be enriched 8 fold for colony forming units 
(CFU) when compared to the unsorted stromal population. This sorted subpopulation 
also proved to exhibit multi-potency when cultured under the correct induction 
conditions. (Gargett et al, 2009; Schwab et al, 2007; Cervello et al, 2011). W5C5
+ 
endometrial stromal cells make up 4.2 ± 0.6% of the total population of stromal cells 
within the tissue, and have also exhibited a significant clonogenetic and multi-lineage 
differentiation ability when compared to their W5C5
- 
counterpart.  W5C5
+ 
sorted 
stromal cells have also shown to give rise to stromal-like tissue in vivo (Masuda et al, 
2012).    
 
A number of other markers that have also been associated with the endometrium. 
Some of these studies have been summarised in table 1.1 (Oliveiria et al, 2012). The 
expression of the survival marker bcl-2, and the haematopoietic markers c-kit (CD117) 
and CD34 have been identified in the endometrium of hysterectomy tissues (Cho et al, 
2004). Their importance as stem cell markers is questionable however, as they are seen 
to be expressed by a wide number of endometrial cells other than the clonogenic or SP 
endometrial cells identified in functional studies (Chan et al, 2004; Kato et al, 2007). 
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Table 1 Summary of stem cell markers in the human eutopic endometrium and in 
endometriotic lesions (Oliveiria et al, 2012)  
 
 
Musashi-1, an RNA-binding protein in neural stem cells and epithelial progenitor cells 
that controls signalling pathways involved in self-renewal, is one such marker that has 
been studied within the endometrium. Musashi-1 expression was found to be present 
within epithelial cells of the endometrial glands and also within the stroma, and was 
seen to co-localise with its molecular target Notch-1 and telomerase.  The cells positive 
for Musashi-1 were seen to be located more abundantly within the basalis when 
compared to the functionalis layer, and were significantly increased in number during 
the proliferative stage of the menstrual cycle over the secretory phase. High levels of 
Musashi-1 expression were also seen within tissue specimens taken from women with 
endometriosis and endometrial cancer (Gotte et al, 2008). A wide range of other 
commonly known stem cell markers including OCT4, NANOG, KLF-4,BMI-1, SOX15, 
SALL4, UTF1 and in some of the literature SOX2, have all shown to be expressed 
within the endometrium (Bentz et al, 2010; Forte et al, 2009; Zhou et al, 2011; Gotte 
et al, 2011). 
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1.5.3 Specific Markers 
OCT4, NANOG, SOX2 
POU class 5 homeobox 1 (OCT4), Nanog homeobox (NANOG) and sex determining 
region Y-box 2 (SOX2) are all core regulators of human and mouse ESC pluripotency. 
They code for transcription factors for genes that control and preserve pluripotency 
within stem cells. Although broadly speaking all of these genes have a similar 
function, strictly speaking are each a little different. Levels of OCT4 must be carefully 
balanced in order to maintain pluripotency, as low levels of expression are seen to 
induce trophectoderm differentiation, whereas over-expression triggers both endoderm 
and mesoderm differentiation.  NANOG has been reported to repress embryonic 
ectoderm differentiation, but does not have any influence over other embryonic 
lineages. In contrast, SOX2 is required for epiblast maintenance. Together these 
transcription factors form a network that regulates self renewal and pluripotency within 
stem cells (Wang et al, 2012; Forte et al, 2009).  
 
The expression of OCT4 has been identified within the endometrium of around 44% of 
women (Matthai et al, 2006). It has been shown not to vary with changes in the 
menstrual cycle and has been found mainly within the stromal cells of the endometrial 
and endometriotic samples with IHC (Bentz et al, 2010; Forte et al, 2009). NANOG 
has also been found within the endometrium and endometriotic tissue, although to a 
lesser extent than OCT4. It is also expressed in human endometrial adenocarcinoma 
(Forte et al, 2009; Zhou et al, 2011; Gotte et al, 2011). Gotte et al provided research 
which found SOX2 expression within the endometrium at a 60-fold lower level than 
OCT4 and NANOG. Gotte et al found that SOX2
+
 stromal cells were significantly 
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raised within the proliferative phase, and found immunoflourescent co-localisation 
with telomerase, a stem cell marker associated with immortality (Gotte et al, 2011). In 
contrast, Forte et al did not find SOX2 anywhere in the normal endometrium or 
endometriotic tissue (Forte et al, 2009).   
 
 CD133 
CD133 is a 5-transmembrane glycoprotein that makes up a part of the prominin family 
of pentaspan membrane proteins. Its expression has been associated with HSCs within 
adult blood, the bone marrow and umbilical cord blood also. In addition, CD133 has 
been found on endothelial, neural and epithelial cells (Rutella et al, 2009). Recently, 
the expression of CD133 has been linked to malignancies of the prostate (Collins et al, 
2005), lung (Eramo et al, 2008), brain (Singh et al, 2003) and ovaries (Ferrandina et al, 
2008). Within childhood it has also been associated with acute lymphoblastic leukemia 
(Cox et al, 2009). CD133
+
 cells taken from human colon cancer, have been shown to 
have the potential to give rise to tumours (Ricci-Vitiani et al, 2007). Following the 
emergence of evidence supporting the existence of cancer stem cells (CSCs) also 
referred to as tumour-initiating cells (TICs), CD133 is now widely considered as a 
marker for such cells, and has been used to isolate TICs in many solid tumours arising 
from different tissues (Rutella et al, 2009). 
 
CD133 has been found within both the glandular and luminal epithelial cells of the 
normal endometrium using the monoclonal antibody AC141, which recognises the 
CD133 epitope (Schwab et al, 2008). CD133 expression has also identified within 
primary human endometrial tumours. CD133
+
 cells possessed the ability to self-renew, 
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formed sphere-like structures in the correct culture environment and gave rise to 
tumours in vivo within immunocompromised mice. CD133
+
 cells have an increased 
proliferative potential and tumourigenicity when compared to CD133
-
 cells and 
showed apparent resistance to commonly used chemotherapy agents (Rutella et al, 
2009; Nakamura et al, 2010).   
 
PODXL 
Podocalyxin (PODXL) is a type I transmembrane protein. It belongs to a large family 
of cell surface protein called sialomucins, and is closely related to the HSC marker 
CD34, and endoglycan. PODXL was first identified on normal kidney glomeruli, on 
the apical surfaces of glomerular epithelial cells called podocytes. Within the kidney, 
PODXL has been found to be important for kidney development, and is seen to control 
podocyte morphology and structural integrity (Nielsen et al, 2009; Doyonnas et al, 
2005). Subsequently, it has been linked to haematopoietic progenitor cells, vascular 
endothelia and also a subset of neurones (Nielsen et al, 2009; Doyonnas et al, 2005). 
PODXL dysregulation has been implicated within a wide range of malignancies 
including breast (Somasiri et al, 2004), testicular (Schopperle et al, 2003), prostate 
(Casey et al, 2006), pancreatic (Ney et al, 2007) and hepatocellular carcinoma (Chen 
et al, 2004). PODXL has been identified as a marker for testicular malignancy within 
the human embryonic carcinoma cell line (Cheung et al, 2011) and has also found 
within all three germ layers during embryogenesis (Nielsen et al, 2009).  
 
Although a recognised stem cell marker, PODXL has still not been linked to the 
endometrium within the literature. Recently within our lab, IHC has confirmed the 
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presence of PODXL within the vascular endothelium and the glandular secretions on 
the apical surfaces of glandular epithelial cells, within the normal endometrium. 
Staining intensity showed that PODXL expression was significantly higher within the 
proliferative phase compared to other phases of the menstrual cycle (unpublished 
data).  
 
hTERT 
Telomerase is a specialised ribonucleoprotein polymerase that catalyses the extension 
of telomeric DNA sequences at the chromosomal ends. By elongating the telomeres, 
telomerase activation provides cellular immortality and is thought to be an essential 
component of oncogenesis and the malignant transformation of most tissue types. The 
functional telomerase enzyme is composed of three major subunits; human telomerase 
RNA (hTR), telomerase protein 1 (TP1) and human telomerase reverse transcriptase 
(hTERT). It is the hTERT subunit which controls telomerase activity, and its mRNA 
expression is reported to correlate to telomerase activity levels as assessed using a 
telomere repeat amplification protocol (TRAP) assay (Paul-Samojedny et al, 2005; 
Kim et al, 2007). In most normal somatic cells, telomerase is usually inactive. 
However in cells which have a high regenerative capacity such as haematopoietic cells, 
cervical epithelial cells and normal endometrial cells, telomerase expression has been 
identified (Paul-Samojedny et al, 2005).  
 
Within the endometrium, the level of telomerase activity has been found to be 
menstrual phase-dependent; highest within the proliferative phase and significantly 
suppressed within the secretory phase (Kyo et al, 1999). This telomerase activity has 
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been localised specifically to the glandular epithelial component of the endometrium 
(Tanaka et al,1998). hTERT mRNA levels are also found to be significantly higher 
within endometrial cancer when compared to levels in the normal endometrium 
(Lehner et al, 2002). More recently, it was shown that hTERT expression is 
significantly increased within patients with endometriosis, and is further evidence to 
support that this benign condition resembles neoplastic disease (Kim et al, 2007). Due 
to its association with limitless replication potential, high telomerase activity is 
detected not only in cancer cells, but within stem cells also. In human keratinocytes, 
stem cells have been shown to be the main source of telomerase activity (Kyo et al, 
1999).  
 
LGR5 
The leucine-rich repeat containing G protein-coupled receptor 5, LGR5 (also known as 
Gpr49), belongs to a family of receptors which are recognised by their seven-
transmembrane-helical topology, including their extracellular N-terminus and 
intracellular C-terminus. These receptors have an important role in forming a 
connection between extracellular information and intracellular signal transduction 
pathways (Krusche et al, 2007). LGR5 is now recognised as a marker for actively 
cycling stem cells in the small intestine, colon and hair follicle (Barker et al, 2007; 
Jaks et al, 2008). Intestinal epithelial LGR5
+
 cells, located at +4 position immediately 
above the Paneth cells in the crypt bases, have now been established as genuine 
intestinal stem cells. With a turnover time of 5 days, the intestinal epithelium is 
recognised as the fastest self-renewing tissue in mammals (Schepers et al, 2011). 
Independent LGR5 knock-in mouse models also demonstrated the highly restricted 
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expression of this gene within a variety of adult tissues, such as the gastric and 
mammary glands, suggesting that it may also be a more general marker of ASCs 
(Barker et al, 2007; Barker et al, 2010). The human endometrium resembles the 
gastrointestinal system with its rapid turnover time, highly regenerative capacity and 
glandular components. Its LGR5 mRNA has been found in the endometrium 
throughout the menstrual cycle and within cultured endometrial epithelial cells 
(Krusche et al, 2007).  
 
ERα, ERβ and PR  
The ovarian hormones, oestrogen and progesterone, are key ingredients for the 
physiological processes that occur within the endometrium. These work by binding to 
and activating the receptors, ER and PR. For many years it was believed that only 
single receptors for ER and PR existed. However, recently evidence has emerged for 
two major isoforms for both ER (α and β) and PR (A and B) exist (Mylonas et al, 
2007).  
 
Oestrogen controls many fundamental processes that occur within the endometrium 
including proliferation and vascularisation, and also up-regulates various genes 
including PR, vascular endothelial growth factor (VEGF) and lactoferrin. ERα and 
ERβ are highly homologous, apart from the C-terminal ligand binding domain and N-
terminal transactivation domain (AF-1) which differ. Both isoforms bind to E2 with 
high affinity. ERα expression rises within the glandular and stromal cells of the 
proliferative functionalis layer, and drops during the secretory phase. The expression 
of ERα is not seen to fluctuate throughout the menstrual cycle within the basalis. 
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Although the role of ERβ within the endometrium is still unclear, unlike ERα, it is 
detected in and therefore associated with the endometrial vascular endothelial cells 
(Critchley et al, 2006; Brosens et al, 2004; Critchley et al, 2009).  
 
PR expression is induced during the proliferative phase of the cycle, driven by 
oestrogen. PR-A is the shorter of the two isoforms and is homologous with PR-B 
except for that it is missing the last 164 amino acids that are present at the end of the B 
subtype. The expression of both PR isoforms is significantly higher within the 
endometrial glands of the functional layer during the proliferative phase of the cycle, 
compared with the secretory phase. However, PR expression is seen to persist within 
the stroma of the functional layer, especially in the cells located closely to the uterine 
vasculature, with PR-A acting as the dominant receptor within these cells. The cells 
within the basalis appear to be controlled differently as PR expression does not 
fluctuate within the glands and stroma of this layer. PR expression also varies between 
the epithelial and stromal cell types. For example within the secretory phase, both 
isoforms of PR are reduced within the epithelial cells of the functional layer, however 
only PR-B declines within the stroma of the same layer (Critchley et al, 2006; 
Critchley et al, 2009).  
 
Regeneration of the endometrium is controlled by the ovarian hormones mentioned 
above and is said to stem from SPCs within the basal layer. Prianishnikov in 1978, 
suggested a theory that still stands today. He claimed that the proliferation of 
endometrial stem cells occurs independently of hormones, which lack the ovarian 
hormone receptors. Daughter cells that arise from these become hormone-sensitive in 
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the presence of oestrogens and acquire ERs enabling them to respond to oestrogen. 
With further replication, these cells later acquire PRs and become sensitive to both 
hormones.  With time, as the cells mature further and move into the secretory phase of 
the menstrual cycle, they become unresponsive to oestrogen but retain their PRs, 
become more differentiated and exhibit secretory changes. According to this proposed 
model, ER and PR are therefore both markers of more differentiated endometrial cells, 
with PR acting as a marker of greater differentiation than ER (Prianishnikov, 1978).  
 
CD9 
Another marker that is important within the endometrium is CD9. CD9 is a 24-27 kD 
glycoprotein that was discovered by Park et al to be strongly expressed within the 
glandular and luminal epithelial cell population of the endometrium equally throughout 
all phases of the menstrual cycle. Stromal cells were seen negative for CD9. CD9 is 
closely linked to integrins and is important for cell adhesion and motility, and therefore 
may have a role in blastocyst implantation and trophoblast invasion. Since this 
discovery was made, CD9 has been adopted by many endometrial studies as a main 
stream surface marker for the identification of endometrial epithelial cells. CD13, also 
known as aminopeptidase N, has also been established as the equivalent surface 
marker for the endometrial stromal population (Park et al, 2000; Kato et al, 2007).  
 
1.6 Stage Specific Embryonic Antigen-1 (SSEA-1) and the 
Endometrium 
As previously described, much work has been dedicated to the identification of 
markers which characterise the stromal stem cell. As yet however, no such markers 
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have been identified for endometrial epithelial SPC population. Our lab has invested 
time and resources into the research and identification of such markers. In recent 
unpublished data, our lab has identified a significant and exciting link between these 
cells and the surface marker, stage specific embryonic antigen-1 (SSEA-1) (Valentijn 
et al, 2013).  
 
SSEA-1, also referred to as Lewis-X (LeX) and CD15, is a carbohydrate moiety 
located on the cell surface. It is expressed by the pluripotent mouse blastocyst, ESCs 
and primordial germ cells (Capela et al, 2006). Within mice, SSEA-1 is present in 
embryonic cancer cells (ECCs) and within late 8-cell embryos. In mice ESCs its 
expression is weak within the early stages and becomes more prominent later on. In 
contrast, SSEA-1 is not expressed within human ESCs or ECCs, but instead they 
express the carbohydrate antigens SSEA-3 and SSEA-4. Hence within humans, SSEA-
1 is described as an ESC early differentiation marker (Muramatsu et al, 2004; Scaffidi 
et al, 2011).  In addition, SSEA-1 expression has been linked to progenitor and stem 
cells in a range of different adult tissues, including the central nervous system, 
cardiovascular system and ciliary epithelium of the eye (Capela et al, 2006; Blin et al, 
2010; Koso et al, 2006). SSEA-1 is also recognised as a marker for tumour-initiating 
cells within studies and has been identified as a marker for cancer stem cells within the 
brain (Son et al, 2009; Scaffidi et al, 2011). Within these tissues the function of SSEA-
1 has been linked to processes including blastomere adhesion, cell-cell interaction and 
growth factor binding (Muramatsu et al, 2004; Capela et al, 2006). As SSEA-1 is a 
fucose-containing trisaccharide, it is must be glycosylated by a group of enzymes 
called fucosyltransferases (FucTs). The role of FucT enzymes is to transfer fucose in 
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α1, 2, α1,3/4 and α1,6 linkages on to a number of glycans and is crucial for the 
production of Lewis systems.  Fucosyltransferase 4 (FUT4) is one of these enzymes 
that regulates carbohydrate antigen expression and whose function has been linked to 
blastocyst attachment. Also linked to leukocyte adhesion, FUT4 was the first 
leukocyte-associated enzyme that was associated with the synthesis of ligands 
including LeY and LeX, or SSEA-1. Investigations into FUT4 within the endometrium 
have shown distinct cyclical changes and hormonal regulation of FUT4 mRNA to 
support that it is up-regulated during the period of implantation and is regulated by 
progesterone. These findings strongly suggest that FUT4 is responsible for the final 
catalysing step in the production of SSEA-1 (Ponnampalam et al, 2008). Within the 
nomenclature, FUT4 is even provided as an alternative name for SSEA-1.  
 
Carbohydrate antigens on the surface of stem cells are useful to enable the isolation 
and identification of such cells, and act as excellent biomarkers. To date, SSEA-1 has 
never been linked to the endometrium and its exact function within the endometrium is 
still unknown. Within our lab, research has shown that SSEA-1
+ 
epithelial cells within 
the endometrium, exhibit many characteristics of SPCs. IHC of full thickness 
endometrium taken from healthy women, shows positive staining for SSEA-1 
exclusively within the glandular and luminal epithelium, but not within the stromal 
compartment. Staining shows the presence of SSEA-1 strongest within the basal 
glands of pre-menopausal women, where endometrial SPCs are thought to arise, and 
has proven to be menstrual-phase dependent with more intense basal staining 
correlating with the early proliferative phase of the cycle. Strong staining is also 
evident within the endometrium of post-menopausal women, in whom only the basalis 
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layer of the endometrium remains. Not only is SSEA-1 present within the correct 
location for epithelial SPCs within the normal endometrium, but SSEA-1 also stains 
positively within eutopic and ectopic endometriotic tissue and within endometrial 
cancer cells, the pathogeneses of which are related to abnormal stem cells. See figures 
1.7 and 1.8 below (Valentijn et al, 2013). 
 
 
 
41 
 
Endometrial epithelial SSEA-1
+
 cells also exhibit high proliferation potential as shown 
by significant expression of the proliferation marker Ki67 and the mitotic marker 
phosphohistone H3. Investigation using the TRAP assay revealed that SSEA-1
+ 
epithelial cells demonstrate significantly higher telomerase activity and telomere 
lengths over their SSEA-1
-
 epithelial counterparts, both features of activated stem 
cells. See figure 1.9 below (Valentijn et al, 2013).  
 
Within 3D culture, which recapitulates the stem cell niche and favours stemness, 
human endometrial epithelial cells have been observed to form hollow gland-like 
structures like those seen within the normal endometrium. Stromal cells are not seen to 
form these spheroid structures in culture. SSEA-1
+
 endometrial epithelial cells show a 
significantly increased tendency to produce a higher number of spheroids than the 
SSEA-1
-
 epithelial cells. They retain SSEA-1
+
 expression until they mature and 
differentiate when expression is restricted to only a few cells. See figure 2.0 below 
(Valentijn et al, 2013). 
42 
 
 
 
This evidence suggests that that SSEA-1 may be a potential marker for enriching 
endometrial epithelial SPCs in humans and that a subpopulation of SSEA-1
+
 may 
contain epithelial SPCs. As previously discussed, in order to establish a SPC 
population, other functional properties including self-renewal, differentiation and in 
vivo behaviour must be evaluated on the SSEA-1
+
 epithelial cell population. In 
addition, to further characterise these cells, their gene expression profile must be 
evaluated to assess whether they possess markers of stemness which would suggest 
stem cell-like behaviour. Gene expression analysis on these cells is therefore the focus 
of this study, and may provide further evidence to suggest that SSEA-1 marks an 
epithelial SPC population within the endometrium.  
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1.7 Clinical Implications and Endometriosis 
The identification, isolation and characterisation of endometrial SPCs have many 
important clinical implications. Stem cell therapy, as already mentioned, is seen as one 
of the most promising techniques for the future of medicine and regenerative therapy. 
Cell therapy can be used to target a wide range of diseases which may affect any part 
of the human body. The endometrium may act as an easily accessible and renewable 
source of such cells. In addition, abnormal endometrial stem cells are postulated to be 
involved in the pathogenesis of gynaecological diseases such as endometriosis, 
endometrial hyperplasia, endometrial cancer and adenomyosis, in association with 
abnormal endometrial proliferation. Therefore the identification of endometrial SPCs 
may not only be used to treat other medical conditions, but will increase our 
understanding of the aetiology of gynaecological conditions such as endometriosis and 
hence their treatment also (Aplin, 2008).  
 
1.7.1 Endometriosis 
Endometriosis is a benign chronic gynaecological condition, defined by the existence 
of endometrial glands and stroma outside of the uterine cavity. It is one of the most 
common conditions seen within gynaecology. It is a common disorder affecting 6-10% 
of all reproductive-aged women, and 35-50% of women who present with the classical 
symptoms of pelvic pain and infertility. There are no differences in the incidence of 
this disease across different races, although Japanese women have been observed to 
have twice the incidence of Caucasian women. The clinical presentations of 
endometriosis may vary from patient to patient however, with some experiencing 
severe symptoms such as dysmenorrhea and dyspareunia, while others remain 
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asymptomatic. Ectopic endometrial tissue is most commonly found on the pelvic 
peritoneum and ovaries, as well as within other pelvic structures such as the fallopian 
tubes, bladder, colon, rectovaginal septum and sacrouterine ligaments. Implants have 
additionally been located at more distant sites such as the pericardium, pleura, lung 
parenchyma and even the brain. Although not life threatening, endometriosis has a 
major economic and social impact. Population-based studies have also discovered that 
women suffering from endometriosis are at an increased risk of developing ovarian 
cancer (Sasson et al, 2008; Overto et al, 2007). 
 
Pathogenesis of Endometriosis 
Despite its common occurrence, the pathogenesis of endometriosis remains unknown 
and has been under extensive investigation for a long time. A number of hypotheses 
exist regarding its aetiology, the most common and widely accepted of these being 
Sampson’s theory of retrograde menstruation.  Sampson postulated that ectopic 
implants arise due to menstrual debris migrating through the fallopian tubes and into 
the peritoneal cavity where they adhere to and invade the peritoneal mesothelium, 
establishing endometriotic lesions. On the other hand, it is thought that 90% of 
menstruating women contain this debris within their peritoneal cavities and therefore it 
is likely that only some of these cells are capable of giving rise to endometriosis in 
certain women. An altered peritoneal environment along with abnormalities in genetic, 
immunologic and environmental factors may also have an influence on their survival 
and proliferative capacity. Strong links between endometriosis and multiple gene loci, 
immune deficiency and also various environmental factors have now been established 
(Figueira et al, 2011; Sasson et al, 2008; Aplin et al, 2008). 
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Other theories include the embryonic rest theory, the lymphovasular metastasis theory 
and the coelomic metaplasia theory. The embryonic rest theory suggests that 
endometriosis is developed from scattered embryonic rests of műllerian origin, which 
when subjected to the correct stimuli, can form endometrial tissue. Alternatively, the 
lymphovascular metastasis theory claims that endometriosis occurs due to the 
lymphovascular spread of menstrual tissue, accounting for the occurrence of 
endometriosis in distant sites such as the lungs and brain. Finally, the colomic 
metaplasia theory suggests that it is the spontaneous metaplasia of the pleural and 
peritoneal mesothelial cells that leads to endometriosis. Although evidence exists for 
each of these theories, it is probably linked to a combination of abnormal biological 
process (Figueira et al, 2011; Sasson et al, 2008).  
 
Diagnosis of Endometriosis 
Being an oestrogen dependent disorder, endometriosis usually affects women during 
their reproductive years when the lesions are stimulated by the ovarian hormones. 
Symptoms are usually the strongest pre-menstrually and are relieved following 
menstruation. Patients may complain with a variety of symptoms, the most common of 
which being pelvic pain. Other symptoms include back pain, dyspareunia, dyschezia 
and pain with micturition. For some, the only presenting complaint may be a history of 
infertility. A family history of endometriosis in a first degree relative may also give 
some indication as to the diagnosis. A thorough patient history can indicate 
endometriosis as a differential but not a definitive diagnosis. It is often misdiagnosed 
as irritable bowel syndrome. On physical examination, signs may be absent, or might 
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present as tender nodules in the posterior fornix or adenexa, cervical motion tenderness 
or even a fixed retroverted uterus (Mounsey et al, 2006). 
 
The gold standard method of making a diagnosis of endometriosis is by direct 
visualisation of the ectopic lesions, usually via laparoscopy. This is commonly 
followed by histological confirmation, in which at least two features are present. These 
features include hemosiderin-laden macrophages, endometrial epithelium or stroma. 
Histologically, these lesions are similar to the eutopic endometrium. Transvaginal 
ultrasonography is used as a valuable investigation to locate retroperitoneal and 
uterosacral lesions, however unfortunately it does not accurately identify peritoneal 
lesions or small endometriomas. Two other tests, including serum cancer antigen 125 
(CA 125) and magnetic resonance imaging (MRI), have both been studied for their use 
in endometriosis, however neither has shown diagnostic accuracy. It is important that 
non-gynaecological causes of pelvic pain are also excluded (Mounsey et al, 2006; 
Bergqvist et al, 1984).  
 
When diagnosing a patient with endometriosis, a clinical staging system is required in 
order to allow clinicians to communicate effectively with one another regarding the 
severity and management. Such a system was revised by the American Society for 
Reproductive Medicine (ASRM) in 1996 and is the most widely accepted system, 
although it does not act as a sensitive predictor for pregnancy following treatment and 
does not link the level of pain with the staging severity (see table 2) (The Practice 
Committee of the ASRM, 2006; ASRM, 1997). 
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Table 2 Revised ASRM classification for endometriosis, 1996 (ASRM, 1997) 
Stage Description 
I  Minimal: Superficial lesions only and may have few adhesions 
II Mild: Stage I and some deep lesions within the cul-de-sac 
III Moderate: Stage II, identification of ovarian endometriomas and increased adhesions  
IV Severe: Stage III, larger endometriomas and extensive adhesions 
 
Treatment of Endometriosis 
The treatments for endometriosis encompass both medical and surgical techniques, and 
focus on relieving pain, preventing disease progression and promoting fertility. The 
choice of management must be made according to a patient’s individual needs, taking 
into consideration the severity of their symptoms, their age and their desire for a 
family. The management available for endometriosis is not curable. In many women, 
the menopause can naturally treat the disease. Several pharmacological options are 
available and are aimed at managing symptoms of pain, and cyclical dysfunction. Non-
steroidal ant-inflammatory drugs (NSAIDs) provide pain relief, whilst the oral 
contraceptive pill (OCP), androgenic agents (e.g. danazol), progestogens and GnRH 
analogues all manage pain whilst simultaneously inducing amenorrheoa. Medical 
management is limited with its use due to their long term side effects and reccurrence 
of endometriosis is common following their discontinuation. Surgical interventions 
provide an alternative, including laparoscopic resection/ablation, which have shown to 
help increase a woman’s fertility. However the effects of surgery may be short lived, as 
within 12 months symptoms of pain reoccur in almost 50% of women and further 
medical treatment is required. More definitively a hysterectomy and bilateral 
salpingoophorectomy can remove symptoms, although this may not be an option for 
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women who still want a family (Mounsey et al, 2006; Overto et al, 2007; The Practice 
Committee of the ASRM, 2006). 
 
1.8 Research Aims and Objectives 
1.8.1 Research Aims 
There are still many unanswered questions about the aetiology surrounding 
endometriosis, and the treatments available are far from ideal. One hypothesis 
regarding the pathogenesis of endometriosis claims that endometrial SPCs are 
abnormally shed into a woman’s peritoneal cavity during menstruation, where they 
adhere and proliferate forming ectopic lesions. An alternative thought is that 
endometrial SPCs may be intrinsically abnormal in women with endometriosis, giving 
them a greater ability to implant and form lesions (Gargett et al, 2010). As yet, unlike 
the stromal population, no markers have been established for endometrial epithelial 
SPCs which would allow their identification and location within the tissue, and would 
enable their isolation and further study.  Prospective isolation of endometrial SPCs 
may provide exciting possibilities for the future of medicine, allowing for their use in 
regenerative medicine throughout the body and an increase in our understanding of 
gynaecological disorders hence improving their treatment.  
 
In our lab, SSEA-1 has been identified as one potential marker located on endometrial 
epithelial SPCs, as these cells seem to possess many qualities that SPCs should have. 
Further evidence is required into the study of the SSEA-1
+
 endometrial epithelial cell 
population in order to definitively conclude that it is an epithelial SPC marker. One 
important area which will allow the further characterisation of these cells and has yet 
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to be defined, is their transcriptional profile for common endometrial markers and 
markers of stemness which control stem cell properties such as self-renewal and the 
maintenance of an undifferentiated state. This may or may not provide further evidence 
for their SPC-like qualities, and therefore is the main focus of this study. 
 
1.8.2 Objectives 
In order to achieve this broad research aim, several specific objectives have been 
identified below to be achieved throughout the course of the study.  
 
Assess the gene expression profile for SSEA-1
+
 epithelial cells versus SSEA-1
-
 
epithelial cells within the normal endometrium, cultured in a normal 2D system.   
In order to do this, quantitative PCR (qPCR) was performed on both cell populations 
to compare mRNA expression of the commonly recognised stem cell markers OCT4, 
NANOG, SOX2, PODXL, hTERT, CD133 and LGR5, and of the endometrial 
differentiation markers ERα, ERβ and PR. Additional markers CD9, as an epithelial 
cell marker, and FUT4, as a marker for SSEA-1, have also been included within this 
study for extra value. 
 
Assess the gene expression profile for SSEA-1
+
 epithelial cells versus SSEA-1
-
 
epithelial cells within the normal endometrium, cultured in a 3D Matrigel 
system.  
SSEA-1 sorted endometrial epithelial cells form gland-like structures in 3D Matrigel, 
similar to the glands seen within the normal endometrium. This 3D culture system is 
said to mimic the endometrial stem cell niche and therefore may favour stemness and 
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prevent differentiation. It is therefore important to assess the gene expression profile, 
looking at the same genes, on SSEA-1
+
 and SSEA-1
-
 cells grown in 3D culture to 
assess if there are any differences with 2D culture. 
 
Compare the gene expression profile for SSEA-1
+
 epithelial cells taken from 
women with a normal endometrium to those with endometriosis.  
As endometriosis is said to have a link with abnormal endometrial SPCs, it is 
important to evaluate whether cells, which express our proposed SPC marker SSEA-
1, show any differences in their gene expression within patients suffering from 
endometriosis. The same genes as previously mentioned was evaluated in both the 
2D and 3D culture systems on these patients
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Chapter 2: Materials and Methods 
All equipment and reagents have been highlighted as ‘bold’ within the text. The 
specifications including the company name and catalogue number of each item can be 
found listed in alphabetical order in appendix II.  
 
2.1 Ethics Approval 
All patients included in the study had given informed written consent prior to 
collection. Ethical approval for the study was granted by the Liverpool (Adult) 
Research Ethics Committee (LREC) (reference 09/H1005/55 and 04/Q1505/112). This 
approval allowed the collection of human endometrial tissue samples from all suitable 
patients, including healthy fertile women and women with endometriosis, who were 
attending the Liverpool Women’s Hospital (see appendix III). 
 
2.2 Patient Recruitment and Sample Collection 
2.2.1 Patient Identification and Recruitment 
Suitable patients undergoing gynaecological surgery were identified following review 
of the planned theatre lists. Once these patients were highlighted, their paper-based 
hospital notes were cross-referenced in order to ensure that they met the correct 
inclusion criteria (see table 3). Suitable patients were provided with a detailed 
description of the purpose of the study and the procedure itself, including any potential 
risks or benefits to the patient. To guarantee informed valid consent, this information 
was provided by staff who were trained in Good Clinical Practice (GCP) and were able 
to consent and recruit the patients for this study. All patients were made aware that 
they had the right to refuse participation within the study and were ensured that this 
53 
 
would not affect their treatment. In addition, patients were also provided with an 
information leaflet to read in their own time (appendix IV) and were given the 
opportunity to ask any questions they may have. Once verbal consent was given, staff 
could then proceed to gain written consent (appendix V). The following demographic 
details were collected for each patient:
participant age, weight (kg), height (cm), body mass index (BMI), 
smoking history, parity, history of miscarriage or termination of pregnancy, the date of 
last menstrual period (LMP), cycle length and the number of days of menstruation, and  
their past medical history (see appendix VI). 
 
2.2.2 Inclusion/Exclusion Criteria 
The study included two groups of patients. The inclusion and exclusion criteria 
specified below were employed in order to select and recruit patients into the study 
(tables 3 and 4). 
Table 3 Control Group Inclusion/Exclusion criteria 
Control Group: Fertile women within reproductive age (n=14)
Inclusion Criteria Exclusion Criteria 
 Women of reproductive age 
 Women undergoing surgery 
for benign gynaecological 
conditions (e.g. laparoscopic 
sterilisation or uterine 
fibroids) 
 Postmenopausal women 
 Women on hormonal therapy 
within the last 3 months 
 Pregnant or breastfeeding 
women 
 History of infertility 
 History of endometriosis or 
gynaecological malignancy  
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Table 4 Endometriosis Group Inclusion/Exclusion criteria 
Endometriosis Group: Women with active endometriosis (n=8) 
Inclusion Criteria Exclusion Criteria 
 Women of reproductive age  
 Women with a surgical 
diagnosis of active eutopic or 
ectopic endometriosis at the 
time of sample collection  
 Women on hormonal therapy 
within the last 3 months 
 Pregnant or breastfeeding 
women 
 
2.2.3 Endometrial Biopsy Collection 
Endometrial biopsies were collected by trained professionals who have been trained in 
the correct method of sample collection from theatre. Depending on the type of the 
surgical procedure planned for the individual, we employed one of two following 
methods to attain an endometrial biopsy. 
 
1. Full Thickness Sampling: 
Full thickness endometrial samples 
were collected from women 
undergoing a hysterectomy. Following 
surgical removal of the uterus, a single 
vertical midline incision was made on 
the posterior surface of the uterus 
from the fundus down to the cervical 
canal (excluding the cervix) using a size 22 carbon steel surgical blade 
(indicated in figure 2.1). This exposed the inner uterine cavity and the 
endometrium. A lateral incision (approximately 25mm wide and 10mm deep) 
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was then made into the uterine wall allowing a full thickness sample to be 
obtained which comprised of the endometrial lining, the endometrial-
myometrial junction and part of the myometrium.  
 
2. Pipelle Sampling:  
For women who were not having a hysterectomy, we collected a pipelle endometrial 
biopsy under anaesthetic before their planned operation had begun. This is a common 
and relatively non-invasive method of endometrial sampling, which is commonly used 
in the outpatient clinic setting. A pipelle is a flexible, blunt plastic tube which collects 
endometrial tissue through suction. Once on the operating table, patients were placed 
in the lithotomy position and a sterile aqueous solution containing chlorhexidine 
gluconate 0.05% was used in order to clean the perineal area externally and the vagina 
and the cervix internally as a part of routine gynaecological surgical preparation. 
Following this, a Sims speculum was inserted into the vagina in order to visualise the 
cervix (this was routinely required as part of the gynaecological surgical procedure 
regardless of whether the patient was in our study, therefore was not over and above 
what was clinically needed for her). Then, a pair of Teales Vulsellum uterine forceps 
was used to hold the anterior lip of the cervix and a pipelle was inserted in through the 
external and internal cervical os towards the fundus of the uterine cavity.  Superficial 
endometrial tissue was collected by the use of rotation and backwards and forwards 
movements of the pipelle, and creating suction by drawing the plunger.  Once the 
necessary amount of endometrial tissue was withdrawn, the pipelle was removed 
completely from the uterine cavity.  
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These tissue collection methods ensured safe, sterile conditions and caused minimal 
discomfort to the patient and therefore in our opinion was ethically acceptable. 
 
2.2.4 Sample Processing 
Once fresh tissue samples had been collected, they were divided into smaller fragments 
for transfer into multiple storage containers in preparation for subsequent laboratory 
experiments. For our study it was essential to collect primary human endometrial tissue 
(without the underlying myometrium) within collection media. For cell culturing, 
biopsies were collected in to Dulbecco’s Modified Eagle Medium/F12 
(DMEM/F12), 1% Fetal Bovine Serum (FBS) and 0.2% Primocin (collection 
medium). This was kept at 4
o
C until ready for subsequent cell culture.  
 
2.3 Isolation of SSEA-1 Enriched and Depleted Populations  
2.3.1 Endometrial Epithelial Cell Isolation 
Biopsy tissue that had been placed in collection media was transferred to a 100mm 
Petri dish along with 1ml of DMEM/F12 to maintain tissue moisture. A surgical blade 
was used to chop up the endometrial tissue into a fine mince consistency. Following 
this, the tissue was transferred into a 30ml universal tube using a 1ml pastette and 
the Petri dish was rinsed with DMEM/F12 to ensure that all remaining tissue was 
collected. The tube was centrifuged at 500g for 5 minutes to collect the cells in pellet 
form. The cell pellet was then resuspended in 4ml DMEM/F12, 500μl 1x collagenase 
(20mg/ml), 100μl 1x dispase (10mg/ml), 100μl 1x DNase (4mg/ml) and 50μl 100mM 
MgCl2.The suspension was incubated for 90 minutes in a shaking water bath at 37
o
C 
to allow digestion into single cells. During this time period, the digest was triturated 
periodically to dissociate digested tissue.   Following this the digest was filtered 
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through a 40μm cell strainer into a 50ml universal tube, and the filter was washed 
thoroughly with around 30-40ml DMEM/F12. The epithelial glands which were too 
big to pass through were retained at the base of the filer, and were named the 
‘retentate’. The stromal cells and contaminating red blood cells which were passed 
through the filter were named the ‘flow through’. The retentate was then back-washed 
using 30-40ml of DMEM/F12 into a 50ml tube, by inverting the cell strainer. Both 
fractions were then centrifuged at 500g for 5 minutes to pellet cells.  
 
For the stromal cell fraction: 
The stromal cell pellet was then resuspended in 4ml DMEM/F12 and layered on to 4-
5ml of Ficoll in a 15ml centrifuge tube. This was subsequently centrifuged at 400g 
for 10 minutes to pellet the contaminating red blood cells. Following this, the stromal 
cells appeared as a single layer at the interface between the Ficoll and the media and 
these were transferred carefully into a 30ml universal tube. The stromal cells were then 
washed with 15ml 1x DMEM/F12 and centrifuged at 500g for 5 minutes. The stromal 
cells were then left on ice. 
 
For the epithelial cell fraction:  
The epithelial cell pellet was resuspended in 1ml DMEM/F12, 1ml 0.25% 
trypsin/EDTA solution (0.125% final concentration), 100μl 1x DNase (4mg/ml) and 
50μl 100mM MgCl2 in a 15ml centrifuge tube. This was incubated at 37
o
C for 20 
minutes and triturated in order to break apart the epithelial glands and liberate the 
single epithelial cells. 1ml of culture medium was then added to inactivate the trypsin. 
The epithelial cell fraction was centrifuged at 500g for 5 minutes and then washed in 
x1 DMEM/F12 in a 30ml universal tube.  
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For both stromal and epithelial cell fractions, the cell pellets were resuspended in 10ml 
of culture (or complete) medium (defined as DMEM/F12, 10% FBS and 50ng/ml 
epithelial growth factor(EGF)) and were plated in either tissue cultureT75cm
2
 
flasks or 100mm Petri dishes, depending on the cell yield obtained. This was incubated 
for 20-30 minutes at 37
o
C. Selective adherence was used to further enrich the epithelial 
and stromal fractions. Unlike epithelial cells which take longer to attach, stromal cells 
attach quickly and readily and therefore adhesion can be monitored with the use of an 
inverted microscope. Non-adherent epithelial cells were transferred to a new culture 
vessel. Selective adherence was repeated if necessary to achieve optimal enrichment. 
Cells were cultivated for up to 3 days, depending on the confluency. The morphology 
of the final cell fractions are shown below in figure 2.2. 
 
 
 
 
 
 
 
 
 
 
The purity of the epithelial cell fraction could be assessed morphologically as 
described above, but also with the use of FC and immunofluorescence (IF) for the 
epithelial marker CD9. The following FC data demonstrates that on days 3-5 of 
culture, greater than 80% of the cells were epithelial in origin (CD9
+
) with less than 
20% stromal cell contamination (CD13
+
) (figure 2.3). 
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FC analysis also confirmed that other cell types including endothelial cells (CD31
+
), 
haematopoietic stem cells (CD34
+
) and leukocytes (CD45
+
) were also present in 
extremely low numbers (less than 3%) (figure 2.4). 
 
2.3.2 Cell Sorting  
Magnetic-Activated Cell Sorting (MACS)  
Following epithelial cell enrichment, anti-SSEA-1(CD15) MicroBeads were used to 
sort the epithelial cell population on the cell surface marker, SSEA-1. The MACS 
sorting of these epithelial cells into SSEA-1
+
 depleted and enriched cell fractions was 
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performed according to manufacturer’s instructions. Cell culture medium was first 
aspirated and the 100mm Petri dish was washed with phosphate buffered saline 
(PBS). Subsequently the cells were trypsinised by using 1ml of 0.05% trypsin/ EDTA 
solution and incubated at 37
o
C for 5 minutes. Following this, 2ml of culture/complete 
medium (containing FBS) was added to stop the reaction and inactivate the trypsin. To 
break apart any cellular aggregates and form a single-cell suspension, the solution was 
triturated before transfer through a 40μm cell strainer which had been placed over a 
50ml Falcon tube. To recover the cell pellet, the cell suspension was then centrifuged 
at 500g for 5 minutes at 4
o
C. Ideally up to 10
7
 cells were recovered at this point. The 
cell pellet was then resuspended in 1ml MACS buffer (composed of PBS, 0.5% bovine 
serum albumin (BSA) and 1mmol ethylenediaminetetraacetic acid (EDTA) and 
was transferred to a pre-chilled 1.5ml microcentrifuge tube. This step washed the 
cells and exposed them to the same conditions as used later for antibody binding, 
before further centrifugation at 700g for 3 minutes. The supernatant was removed and 
the cell pellet gently resuspended in 80μl of buffer and 20μl of anti-SSEA-1(CD15) 
MicroBeads. This was mixed well and incubated at 4
o
C for 20 minutes in a refrigerator 
to allow magnetic labelling of the cells. The microcentrifuge tube was flicked 
periodically to ensure that any settled cells were resuspended. This cell suspension was 
washed in 1ml of Miltenyi buffer and centrifuged at 700g for 3 minutes as before. This 
step was then repeated for a second time following aspiration of the supernatant. In 
order to magnetically separate the labelled cells, a MACS separation column was 
placed in a magnetic field using a MACS separator. The separation column was 
prepared by adding a 30μl yellow pre-filter and pre-wetting it with 500μl of buffer.  
500μl of this buffer was also added to the cell pellet following aspiration of the 
supernatant, before loading the cell suspension onto the column. The cell suspension 
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was washed through the column with 500μl of buffer twice, and this ‘flow through’ 
was collected into a 1.5ml microcentrifuge tube  containing the unlabelled SSEA-1
+
 
depleted cells. The column was subsequently washed for a third time with 500μl of 
buffer, however this ‘waste’ solution was discarded into a separate tube. The column 
was then removed from the magnetic cell separator and placed on a third tube before 
washing it with 1.5ml of buffer to collect the ‘eluate’ containing the magnetically 
labelled SSEA-1
+
 enriched cells. Care was taken to only remove the magnetic field 
once the column was carefully placed over the collection tube. Finally, in order to 
recover the cell pellets from the ‘eluate’ and ‘flow through’ cell suspensions, both 
fractions were centrifuged at 700g for 8-10 minutes to collect as many cells as 
possible.  
 
 
  
 
 
 
 
 
 
 
Western blotting confirmed that the SSEA-1
+ 
fraction was indeed enriched for SSEA-1 
(figure 2.6). With the use of FC analysis, expression of SSEA-1 was routinely seen 
within 20-30% of the cultured epithelial cells. Stromal cells did not appear to express 
SSEA-1, as evidence by IHC.  
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Fluorescence-Activated Cell Sorting (FACS) 
With the use of cytocentrifugation and IF, our lab has seen that the cell purity and 
efficiency obtained by MACS for SSEA-1, is around 70% (figure 2.7) compared to 
FACS which has an efficiency of greater than 90%. For this reason, some samples 
were sorted on SSEA-1 and the epithelial marker CD9 using FACS, in order to verify 
the results obtained with MACS sorted samples. A limited number of samples could be 
sorted using FACS throughout the project due to the inaccessibility of the FACS 
instrument and the need for a high number of cells.  
 
FACS instruments consist of a flow cytometer with the additional ability to sort cells 
according to their fluorescent signal. Fluorescently labelled single-cell suspensions 
flow past an excitation source (usually a laser light) of a single wavelength, in a liquid 
phase. The stream of cells is broken into individual droplets containing single cells. As 
they pass through the beam they cause the light to scatter, and this is analysed by 
detectors which can assess the cell structure (FC). In addition to this cell analysis, they 
can also be sorted with the use of electrostatic deflection which diverts cells into 
containers based upon their charge.  
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For FC, monolayer cultures of epithelial cells were trypsinised in to single cell 
suspensions as described for MACS (see section previous). Cells were labelled in 
FACS buffer (containing 0.5% bovine serum albumin (BSA) and 1mM EDTANa2 in 
PBS) with either AlexaFluor 488-CD9, PE-SSEA-1 or both according to the 
manufacturer’s instructions.  Unlabelled cells and cells labelled with isotype matched 
antibodies served as controls. Cells were prepared and labelled by Anthony Valentijn 
and analysed and sorted by Stuart Marshall-Clarke or analysed alone by Sandra Rak-
Razewska. 
 
As with MACS, cultured epithelial cells which had been grown in monolayer were 
trypsinised in a 100mm culture dish by adding1ml 0.05% trypsin/EDTA solution and 
incubating at 37
o
C for 5 minutes. 2ml of culture media containing FBS were then 
added to inhibit the trypsin. To break apart cell aggregates the solution was triturated 
and transferred through a 40μm cell strainer placed over a 50ml Falcon tube. Once 
centrifuged at 500g for 5 minutes at 4
o
C the cell pellet was recovered. For FACS, at 
least 10
7
-10
8
 cells were required per test. Controls included unlabelled cells and cells 
which had been labelled with isotype controls for the fluorochromes which were used. 
The cell pellet was then resuspended in 100μl FACS buffer and between 0.5-1μg 
(dependent on the formulation of the manufacturer) of unlabelled or fluorescently 
labelled primary antibody for SSEA-1 and CD9, labelled with either Fluorescein 
(FITC)/AlexaFluorR 488 or Phycoerythrin (PE) as recommended by the 
manufacturers. This was then incubated in a dark fridge for 20-30 minutes. Following 
this, 1ml of FACS buffer was added and the tube was centrifuged at 700g for 3minutes 
at 4
o
C. The supernatant was aspirated and the cell pellet was again resuspended in 1ml 
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of buffer before being centrifuged as before. In the case of the unlabelled primary 
antibody, the cell pellet was resuspended in 100μl FACS buffer and 0.5-1μg of the 
labelled secondary antibody was mixed in. This was incubated for 20-30 minutes at 
4
o
C and washed twice with 1ml of buffer.  The unlabelled cells were then treated in the 
same way as cells mixed with the labelled antibody in the following step. If the 
labelled primary antibody was used, the cells were instead resuspended in 500μl FACS 
buffer and analysed as quickly as possible or fixed with neutral buffered formalin 
(NBF)/PBS and stored at 4
o
C for up to one week.  
 
Once the cells had been prepared as described above, they were analysed using the 
FACSCalibur cytometer along with Cell Quest Acquisition and Analysis software 
(CellQuestPro version). Cell sorting was performed using a FACS Ariall cell sorter 
and the data was finally analysed with FACSDiva software (version 6.1.3), BD 
Biosciences.  
 
2.4 Organoid Culture 
Mimicking the in vivo environment of the endometrial stem cell niche, endometrial 
epithelial cells were also cultured in 3D Matrigel, as well as the 2D culture previously 
described. Basement membranes are thin extracellular matrices that in vivo underlie 
cells. BD Matrigel
TM 
represents a solubilised form of basement membrane. Cells from 
MACS purification representing SSEA-1 enriched and depleted fractions were 
reuspended in Matrigel at an initial density of ~100,000 cells/100μl. This was 
subsequently diluted serially two-fold from ~100,000 cells/100μl to ~3000 cells 
/100μl. 50μl cells was plated in duplicate in wells of a 24-well tissue culture and the 
Matrigel allowed to gel at 37
o
C for 30 min prior to adding 1.0ml DMEM/F12 
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supplemented with 1x insulin-transferrin-selenium and 50 ng/ml EGF. The medium 
was replaced every 3 days and the culture was monitored over a 10-12 day period. In 
3D culture endometrial epithelial cells formed gland-like structures also referred to as 
organoids/spheroids similar to the glands seen in the endometrium. This mainly arose 
from the SSEA-1
+
 cell population (figure 2.8).  
 
 
2.5 RNA Extraction  
2.5.1 RNA Extraction  
In order to extract total RNA from SSEA-1 sorted cells and organoids, the TRIzol® 
reagent method was implemented according to the manufacturer’s instructions. 
Initially, 1ml of TRIzol® reagent was added to the cell pellets in order to lyse the 
cells. In the case of positive controls and organoids which had been obtained from a 
b c 
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culture dish, culture medium was first aspirated and 1ml of TRIzol® reagent was then 
added directly to the dish. This was pipetted thoroughly to obtain a homogenous 
suspension before being transferred to a 1.5ml microcentrifuge tube.  In order to ensure 
that the maximum numbers of cells were introduced into the TRIzol® suspension, 
cells were gently pipetted to ensure that the cells had visually disintegrated. In the 
instance that RNA had to be isolated from tissue samples, a hand-held homogeniser 
was used instead. Next, 200µl of chloroform (or 1/5
th
 of the initial volume of 
TRIzol®) was added to the solution. These microcentifuge tubes were then shaken for 
15 seconds and centrifuged at 12,000g for 15 minutes at 4
o
C.  At the end of this step, 
three phases could be distinguished. These included a clear upper aqueous layer which 
contained the RNA, a white interphase containing proteins which had not been fully 
denatured and a lower red organic phase made up of DNA and other proteins. The 
RNA or aqueous phase was then transferred into fresh 1.5ml tubes, ensuring that a 
clear margin was left above the interphase in order to minimise the risk of any 
contamination from DNA or protein. In cases where RNA was extracted from a small 
number of cells, the aqueous phase was added to separate tubes containing 1µg/µl of 
glycogen. The glycogen acts as a carrier and is useful when small amounts of RNA are 
extracted. The remaining microcentifuge tubes containing the lower two phases were 
discarded at this point into ‘TRIzol waste’. In order to precipitate the RNAs, 500µl of 
2-propanol (50% of the original volume of TRIzol® used) was added and the 
solution mixed by inverting the tubes 6 times. These were then left to incubate for 10 
minutes at room temperature. Subsequent to incubation, the tubes were centrifuged at 
12,000g for 10 minutes at 4
o
C to produce visible RNA pellets at the bottom of the 
tubes. The supernatant was removed and the remaining pellet was washed with 1ml 
of 75% ethanol and was centrifuged at 7,500g for 5 minutes at 4
o
C. The ethanol was 
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then discarded, and the RNA pellets left to dry for a few minutes at room 
temperature. As the RNA was then used immediately for cDNA synthesis, the pellets 
were dissolved in 15-25µl nuclease free water depending on their size.  
 
2.5.2 Verification of RNA Integrity by Gel Electrophoresis 
 RNA integrity was verified with the 
use of electrophoresis on a 1% agarose 
gel (made in 1x tris–acetate–
ethylenediamine tetraacetic acid 
(TAE)). This was achieved by initially 
dissolving 2g of agarose power in 
200ml of 1x TAE buffer (recipe in table 
3). This suspension was heated to boiling point in a microwave before allowing it to 
cool to 60C. 4μl of ethidium bromide (2µl per 100ml; 0.5μl/ml) was then added and 
mixed into the molten agarose before pouring it into a plastic electrophoresis case of 
the appropriate size. Ethidium bromide staining is used to enable visualisation of the 
28S and 18S ribosomal RNA bands. The gel was then left to set for around 30 minutes 
at room temperature. Samples to be loaded were prepared during this time included 1μl 
of RNA, 2μl of 5x DNA loading buffer and 7μl of nuclease-free water, making a final 
volume of 10μl. The 5x loading buffer allowed visual control of the electrophoresis 
and provided density to the samples. It was added to each sample to a 1x final 
concentration. The gel was then immersed in the 1x TAE buffer and a 100V electrical 
current was applied. RNA of good quality appeared as two clear rRNA bands (28S and 
18S) and in most cases samples showed a third band nearer the end of the gel 
representing 5S. Degraded RNA appeared on the gel as a smear. Bands were observed 
Recipe for 10x TAE 
NaCl 48.4g 
Glacial Acetic Acid 
(17.M) 
11.4ml 
EDTA 3.7g 
Distilled H2O Up to 1L 
Table 5: Recipe for 10x TAE 
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under a UV light in a Molecular Imager® Gel DocTM XR from Bio-Rad. 
Representative RNA Bands for SSEA-1 sorted samples are shown below (figure 2.8): 
Normal Endometrial Samples (labelled ‘N’): 
1. MACS Sorted 
 
 
 
 
 
 
 
 
 
2. FACS Sorted 
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Endometriosis Samples (MACS only) (labelled ‘E’):      
 
Organoids (MACS only): 
 
 
 
 
 
2.5.3 RNA Quantification: NanoDrop 
In order to determine the RNA concentration within each sample, RNA samples were 
loaded onto a NanoDrop
TM
 1000 Spectrophotometer following the manufacturer’s 
guidelines. Firstly, the Nanodrop 2000 software was loaded and the machine was 
verified with the arm of the Nanodrop facing downwards. 1μl nuclease-free water was 
then loaded to blank the machine. This nuclease-free water should be the same as that 
used to dissolve the initial RNA pellet.  Following this, 1µl of the RNA samples were 
loaded in succession and the RNA concentrations measured. The 260/280nm 
absorbance ratio, reflecting the purity of the RNA, was also measured. Pure samples 
have values between 1.8 and 2. Quantification of the RNA at this stage allowed 
equalisation of the RNA input within the next stage of DNase treatment. On 
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completion of use, the NanoDrop was cleaned with 1μl nuclease-free water (see 
appendix VII for nanodrop values).  
 
2.6  cDNA Synthesis 
2.6.1 DNase Treatment  
In order to remove any contaminating genomic DNA from the RNA samples, the RNA 
was subsequently treated with deoxyribonuclease (DNase) enzyme. Dependent on 
previous Nanodrop readings, the volume of RNA was altered accordingly in order to 
equalise the RNA concentrations which were input into the DNase treatment step. For 
each sample a maximum of 8μl of RNA (typically a total of approximately 1000-
1500ng), 1μl RQ1 DNase Buffer and 1μl RQ1 DNaseI (1000U/ml) were placed into 
a 0.2ml PCR tube and incubated for 30 minutes at 37
oC.  Following this, 1μl of RQ1 
DNase Stop Solution was added and incubated for a further 15 minutes at the higher 
temperature of 60
o
C in order to completely inactivate the DNase. The DNase-treated 
RNA was then used immediately for cDNA synthesis and the remaining volume was 
stored at -20
o
C until it was next required. 
2.6.2 cDNA Synthesis 
For cDNA synthesis, 4μl of the DNase-treated RNA, 2μl of random hexamers 
(100ng/μl), 1μl of dNTP mix and 7μl of nuclease-free water were added into a fresh 
0.2ml tube.  This was incubated at 65
o
C for 5 minutes and then placed on ice for 1 
minute. Next, 4μl of 5x 1st strand buffer, 1μl of dithiothreitol (DTT) (0.1M) and 1μl 
of the reverse transcriptase enzyme SuperScript III (200U/μl) were added to the tube, 
mixed gently and left to stand at room temperature for 5 minutes. Finally this was 
incubated for 60 minutes at 50
o
C followed by a further 15 minutes at 70
o
C in order to 
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inactivate the enzyme.  The cDNA was diluted 1:3 (v/v) with nuclease-free water 
before being stored at -20
o
C until further use.  
 
2.7 Real-Time Polymerase Chain Reaction  
2.7.1 Primers 
All of the primers used within this study were purchased from Sigma-Aldrich in 
lyophilised form. The primers were dissolved in 1ml of nuclease-free water to make 
a concentrated stock, which was then diluted to make working stocks of 6.25pmol/μl 
concentration. Primers which were designed in house were sequenced by the 
Sequencing Service, University Dundee, UK. Details about the primers used within 
this study are included in table 6. 
Table 6 Human specific primer pairs 
Gene Sequence Product 
Size  
(bp) 
Annealing 
Temperature 
(
o
C)  
Source 
OCT4 F: 5’AGAACCGAGTGAGAGGCAA3’ 
R: 5’CTCTCGTTGTGCATAGTCGC3’ 
176 56 In house 
NANOG F: 5’CGGAGACTGTCTCTCCTCTT3’ 
R: 5’GTTCTTGCATCTGCTGGAGG3’ 
240 56 In house 
SOX2 F: 5’CGAGATAAACATGGCAATCAAAAT3’ 
R: 5’AATTCAGCAAGAAGCCTCTCCTT3’ 
85 56 Wong et al, 
2010 
PODXL F: 5’CCATCGTCTGCATGGCATCA3’ 
R: 5’CTGTCTGCAGCTCCTCTGTT3’ 
114 56 In house 
CD133 F: 5’TGCAACAGCATCAGATTGTC3’ 
R: 5’TACCTGCTACGACAGTCGTG3’ 
199 56 In house 
CD9 F: 5’GACACCTACAACAAGCTGAA3’ 
R: 5’ACAGGACTTCACGGTGAAGG3’ 
165 56 In house 
ERα F: 5’TGATTGGTCTCGTCTGGCG3’ 
R: 5’CATGCCCTCTACACATTTTCCC3’ 
101 56 Henderson, et 
al 2003 
PR F: 5’CAGTGGGCGTTCCAAATGA3’ 
R: 5’TGGTGGAATCAACTGTATGTCTTGA3’ 
83 56 Henderson et 
al. 2003 
FUT4 F: 5’CAGCTGGTTCGAGCGGTGAAGCCGCGCT3’ 
R: 5’CAGAAAAACGTGAATCGGGAACAGTTGTGT3’ 
435 60 Ponnampalam 
et al, 
2008  
ACTB F: 5’AGTGTGACGTGGACATCCGCA3’ 
R: 5’GCCAGGGCAGTGATCTCCTTCT3’ 
112 56 Marullo et al, 
2010 
GAPDH F: 5’GTGGTCTCCTCTGACTTCAA3’ 
R: 5’TCTCTTCCTCTTGTGCTCTT3’ 
212 56 In house 
YWHAZ F: 5’CGTTACTTGGCTGAGGTTGCC3’ 
R: 5’GTATGCTTGTTGTGACTGATCGAC3’ 
69 56 Marullo et al, 
2010 
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2.7.2 Real-Time/Quantitative PCR (qPCR) 
In order to quantify the level of mRNA expression for the specific genes identified in 
the table above, real-time qPCR was performed using SYBR green in a 20µl PCR 
reaction: 10µl KAPA SYBR FAST qPCR Mix Master (2x), 1µl forward primer 
(6.25pmol/µl or 0.3125μM), 1µl reverse primer (6.25pmol/µl or 0.3125μM), 1µl 
cDNA template and 7µl nuclease-free water. qPCR allows both the detection and 
quantification of the amount of amplified double stranded DNA by measuring the level 
of fluorescence. SYBR green is a non-specific fluorescent dye which intercalates with 
double-stranded DNA only, emitting a fluorescent signal of a specific wavelength on 
binding. The intensity of the signal is therefore relative to the number of copies 
amplified, and increases with increasing cycle number. To minimise the variations 
made when pipetting, general primer and template master mixes were prepared before 
making up the 20μl PCR reactions. For each PCR reaction, 11μl of the template master 
mix (containing the KAPA SYBR FAST qPCR Mix Master (2x) and template) and 9μl 
of the primer master mix (containing the specific forward and reverse primers and 
nuclease-free water) were mixed in a 0.2ml PCR tube, to make a final volume of 20μl. 
qPCR reactions were performed in triplicate for each template using the Corbett 
Rotor-Gene 3000 centrifugal real-time cycler (36 well rotor) along with Rotor Gene 
Software (Version 6) according to the following cycling conditions: 95
o
C for 10 
minutes to activate the DNA polymerase, followed by 35-40 cycles of denaturation at 
95
o
C for 6 seconds, annealing at 55-60
o
C for 20 seconds and elongation at 72
o
C for 30 
seconds. For generation of a melt curve within the final stage of each run, the 
temperature would ramp from 72
o
C up to 95
o
C, rising by 1
oC with each step. ‘No 
template’ reactions were included with each PCR run as a negative control, in order to 
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identify the presence of any contamination. Positive controls were also included to 
ensure that the specificity of the primers (listed in table 7). 
Table 7 Primer positive controls 
Positive Control Primers 
Full thickness endometrium 
(Proliferative phase) 
ERα, PR, PODXL, CD9, GAPDH, ACTB, 
YWHAZ 
  
Human ESCs: Hues 7, passage 28 OCT4, NANOG, SOX2 
  
HT29 CD133, 
  
Secretory Phase Endometrium FUT4 
 
The amplification products were initially verified using gel electrophoresis to confirm 
the correct band sizes and hence the correct amplicon. For further experiments, the 
melt curve generated by the software with each run, gave sufficient evidence of the 
correct product and also additional information of any non-specific amplification or 
primer dimers. In order to calculate relative mRNA expression, all genes were 
compared to the reference gene YWHAZ (Marullo et al, 2010), which was included 
within each run.  
 
 
2.7.3 Verification of cDNA Synthesis 
In order to verify that the cDNA synthesis protocol worked correctly, the template 
was tested using one qPCR experiment. The templates used in this run were RNA, 
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DNase treated RNA and cDNA for a particular sample, in addition to the no-template 
control (NTC). For this run only, PCR reactions were not performed in triplicate but 
as single reactions using the primers for the reference gene alone. If the DNase 
treatment is successful, RNA should show some amplification due to contaminating 
genomic DNA; however, this should be eliminated following DNase treatment. High 
amounts of amplification should be evident when using cDNA as template.   
 
Quantification Analysis 
 
 
 
Melt Curve Analysis: 
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2.7.4 Efficiency of Primers 
In order to calculate the relative gene expression, the efficiency of each primer set 
had to be determined using standard curves to assess the linearity of DNA 
amplification. To achieve this, serial dilutions of cDNA template from a positive 
control were used to perform a qPCR run for each primer set. Serial dilutions of the 
cDNA diluted in nuclease-free water were made up according to the following 
diagram (figure 3.6). 
 
Note that the ‘undiluted cDNA’ was diluted 1:3 (v/v) with nuclease free water (as 
described within the cDNA synthesis section 2.6), and this was considered to be the 
1x sample. The remaining dilutions were made up by diluting 1:5 (v/v) from the 
previous dilution. qPCR reactions were set up as described previously using three 
technical replicates. This generated a standard curve for each primer set which 
reported their efficiency. The efficiency of a primer is dependent on the amount of 
specific PCR product which is yielded at the end of each cycle. Ideally a primer 
which is 100% efficient should produce a 2-fold increase in PCR product with each 
cycle. This is denoted as an efficiency of 1 on the Rotor-Gene 6 software. A 
representative standard curve for NANOG has been shown below (see appendix VIII 
for all standard curves).  
Undiluted 
cDNA 1x Undiluted 
cDNA  
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2.7.5 Calculating Relative Expression 
For each standard curve, sample dilutions were given arbitrary numbers of copies 
ranging from 0.32 up to 1000, as shown in table 8 below. 
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Table 8 Theoretical concentrations for serial dilutions 
Template Dilution Given Concentration 
(copies/μl) 
1x 1,000.00 
1/5x 200.00 
1/25x 40.00 
1/125x 8.00 
1/625x 1.60 
1/3125x 0.32 
 
 
Following each qPCR run, thresholds were set at the exponential phase of the 
amplification profile. Ideally this would be set where the regression correlation 
coefficient (R
2
) is optimal, however to allow comparison between all genes and the 
standard curves across all samples, the threshold was set to a fixed value of 0.07. 
Using this threshold, the cycle number (Ct) values, indicating the number of thermal 
cycles needed for the fluorescent signal in a given sample to reach the threshold, 
could be deduced. Using the standard curves, the reaction efficiency based on the 
efficiency of the primer pairs could be calculated using the formula Efficiency*=10
(-
1/m) – 1, where m represents the gradient of the regression line. The 
theoretical/arbitrary copy numbers allocated to the varying dilutions was plotted 
against the Ct values to form a standard curve for each primer pair. The equations of 
these curves were used within qPCR mRNA analysis on the target samples, in order 
to calculate the relative number of copies of mRNA within them (see table 9).   
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Table 9 Standard curve concentration equations 
Primer 
Set 
Melting 
Point (
o
C) 
Efficiency Standard Curve 
Concentration Equation 
(Conc=) 
OCT4 87.8 0.95 10^(-0.289*Ct + 10.868) 
NANOG 84.3 0.91 10^(-0.282*Ct + 8.505) 
SOX2 77.5 0.73 10^(-0.245*Ct + 9.238) 
PODXL 87.3 1.02 10^(-0.306*Ct + 11.058) 
CD133 83.8 1.01 10^(-0.303*Ct + 9.615) 
FUT4 85.8 0.74 10^(-0.240*Ct + 9.989) 
PR  80.7 1.08 10^(-0.318*Ct + 11.543) 
ERα 83.5 1.01 10^(-0.304*Ct + 11.066) 
CD9 85.7 1.26 10^(-0.356*Ct + 12.876) 
ACTB 86.7 0.86 10^(-0.269*Ct + 8.418) 
YWHAZ 81.0 1.14 10^(-0.303*Ct +9.615) 
 
2.7.6 Gel Electrophoresis: FlashGel System 
In order to confirm that the primer sets were amplifying 
the specific PCR products, gel electrophoresis was used in 
order to check that these products were of the correct band 
sizes (as mentioned in section 2.7.2). Unlike the system 
used to check RNA bands with self-made agarose gels 
(section 2.5.2), the PCR products were verified using the 
FlashGel system from Lonza. This system is the fastest 
way to separate DNA using disposable, pre-cast and pre-
stained agarose gel cassettes whilst allowing real time 
monitoring of DNA migration. The FlashGel system is not 
only advantageous in terms of time; however it is also a more sensitive and safer 
method, eliminating exposure to dangerous chemicals such as ethidium bromide and 
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also UV illumination. As special RNA cassettes were needed, this system was not 
ideal for visualising RNA bands which appear as a smear on the DNA cassettes. 
Therefore the previously described method of gel electrophoresis was used for this. 
The Flashgel system was used according to the manufacturer’s instructions. Samples 
to be loaded were first prepared on parafilm, including 1μl of PCR product, 1μl 1x 
FlashGel™ Loading Dye (5x) and 3μl nuclease-free water to make up a maximum 
final sample volume of 5μl per well. Next, the white well seal was removed from 
either the two-tier 16+1 2.2% agarose cassette whilst taking care not to remove the 
clear side vents. Sample wells were then flooded with distilled water and by tilting 
the cassette, excess fluid which had moved to the edge of the cassette could be 
blotted away using tissue paper. The wells were not blotted directly. Following this, 
the cassette was placed into the FlashGel dock and the samples were loaded, 
avoiding the first well. The first well was loaded with 3μl of the FlashGel® DNA 
Marker 100bp-4kb or the FlashGel
®
 Quantladder (100bp-1.5kb). Next, the 
voltage leads were assembled and the power supply and light were both turned on. 
The voltage was set to 270V and the gel was left to run for between 2-5 minutes until 
the desired separation had been achieved. When completed, the power was then 
switch off and the leads disconnected. The bands were then recorded and an image 
captured using the FlashGel™ Camera. 
 
2.8 Immunofluorescence  
IF works by using the specificity of antibodies to detect target antigens within a cell. 
This binding can by visualised with the use of fluorescent dyes which emit light of 
different wavelengths following the absorption of excitation light. There are two 
main methods of IF labelling; direct and indirect labelling. For the purpose of this 
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study, indirect labelling was used 
involving an unlabelled primary 
antibody which was specific to the 
molecule of interest. A secondary 
antibody, tagged with a fluorescent 
dye, was then targeted towards the 
constant portion of the first antibody (figure 4.1). Unlike IHC, in our study IF 
allowed dual labelling of the protein of interest and cytokeratin (CK), a membrane 
protein found within the cytoskeleton of epithelial cells. This allowed the exclusion 
of any staining that may have arisen from other contaminating cell types. 
 
Due to time restraints, this was performed on one sample taken from a healthy 
female of reproductive age with no gynaecological pathology. Following MACS 
sorting (described in section 2.3.2), the endometrial SSEA-1
+
 and SSEA-1
-
 epithelial 
cells were plated onto two separate 8-well chamber slides at a seeding density of 
approximately 5x10
3 
cells/well (dependant on the yield of SSEA-1
+
 cells). Following 
this the cells were left to adhere and proliferate within the wells for approximately 2 
days before fixing. In order to fix the cells, they were washed twice with 1x PBS. 
Each was done for 5 minutes at room temperature. 10% NBF was then added for 10 
minutes at room temperature and the chambers were subsequently washed three 
times with 1x PBS before proceeding onto the staining protocol. 
 
In order to permeabilise the cell membranes, the PBS was aspirated and the wells 
were covered 0.2% triton/EDTA and incubated for 5 minutes at room temperature. 
Following this the wells were washed once with PBS and incubated with blocking 
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serum for one hour at room temperature in order to block non-specific sites. The 
block/diluent was prepared with1% BSA, 10% normal goat serum (NGS), 0.05% 
tween and PBS within a 100ml universal tube. Within this time appropriate 
dilutions of the primary antibodies and CK (for dual labelling) were prepared 
according to the concentrations indicated in the table and the plan of the 8-well 
chamber slides below. These were diluted with the diluent previously prepared (table 
10). Following the blocking stage, 200μl of each the appropriate antibody was 
applied to each well and incubated at 4
o
C overnight. Note that block was left on one 
well per chamber which served as a negative control with no primary antibody (see 
figure 4.2). 
Table 10 Detailed specifications of primary antibodies 
Primary 
Antibody 
Supplier Catalogue 
Number 
Clone Concentration Polymer Mono/ 
polyclonal 
OCT4A Cell 
Signalling 
Technology 
C30A3 C30A3 1:50 Rabbit 
(Rb) 
Monoclonal 
NANOG Cell 
Signalling 
Technology 
D7364 D73G4 1:100 Rabbit 
(Rb) 
Monoclonal 
PODXL R&D 
Systems 
MAB1658 222328 1:100 Mouse 
(Ms) 
Monoclonal 
Telomerase Abcam ab27573  1:500 Rabbit 
(Rb) 
Polyclonal 
ERα Epitomics S1353  1:100 Rabbit 
(Rb) 
Polyclonal 
ERβ Serotec MCA1974
5 
PPG5/10 1:50 Mouse 
(Ms) 
Monoclonal 
PR Dako M3569 PgR636 1:200 Mouse 
(Ms) 
Monoclonal 
CK18 Dako M7010 DC10 1:200 Mouse 
(Ms) 
Monoclonal 
CK7 Cell 
Signalling 
Technology 
4898S R458 1:200 Rabbit 
(Rb)  
Polyclonal 
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Following overnight incubation, the wells were washed three times with PBS and 
200μl of the secondary antibody was added to each well. The secondary antibodies 
were diluted to a final concentration of 1:1000. These antibodies were chosen to 
ensure that all CK was stained green and that the target protein was stained red. The 
top four wells of each chamber was incubated with anti-rabbit Alexa Fluor
®
 555 
(red) and anti-mouse Alexa Fluor
®
 488 (green), and the bottom four wells were 
stained with anti-rabbit Alexa Fluor
®
 488 Conjugate (green) and anti-mouse Alexa 
Fluor
®
 555 (red) (as indicated in figure 4.2). 
 
Table 11 Detailed specifications of secondary antibodies 
 
 
Details of the secondary antibodies can be seen in the table 11 above. The chambers 
were then left to incubate at room temperature in a dark cupboard for 45 minutes, 
Secondary 
Antibody 
Supplier Catalogue 
Number 
Concentration Species Polymer 
Alexa Fluor® 488 
Conjugate (green) 
Cell Signalling 4408 1:1000 Goat Anti-
mouse 
Alexa Fluor® 555 
Conjugate (red) 
Cell Signalling 4409 1:1000 Goat Anti-
mouse 
Alexa Fluor® 488 
Conjugate (green) 
Cell Signalling 4412 1:1000 Goat Anti-
rabbit 
Alexa Fluor® 555 
Conjugate (red) 
Cell Signalling 4413 1:1000 Goat Anti-
rabbit 
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allowing time for the secondary antibodies to bind. The chambers were subsequently 
washed with PBS three times and using the special removal tool the glass chamber 
was separated from the slide below. The slides were quickly dipped into water to 
maintain moisture before adding one drop of mounting medium with DAPI onto 
each well. The DAPI allowed visualisation of cell nuclei with blue staining.  
Carefully, one rectangular 22x40mm coverslip was placed on each slide so that all 
wells would be covered and any bubbles were removed. The slides were then 
visualised using a fluorescence microscope and images captured using NIS 
Elements-F software. MacBiophotonics ImageJ software was used to overlay the 
images taken of the different fluorophores.  IF staining of passage 28 Hues7 humam 
embryonic stem cells (provided by Virginie Mournetal, Liverpool Stem Cell Group) 
were also included as a positive control in order to verify the staining shown by the 
OCT4A and NANOG antibodies.  
 
2.9 Statistical Analysis 
Data was considered to be non-normally distributed as recommended by a 
professional statistician and confirmed by SPSS normality testing using the Shapiro-
Wilk’s test (p-value less than α=0.05), therefore non-parametric methods of data 
analysis were used. Statistical analysis was performed using the non-parametric 
paired Wilcoxon signed-rank test (WSR test), in order to compare the differences in 
gene expression between the SSEA-1
+
 and SSEA-1
-
 fractions, and also across the 
normal and endometriosis groups. The Mann-Whitney U-test (MWU test) for 
nonparametric independent groups was used to check for baseline differences in 
patient demographics between the normal and endometriosis groups. Summary 
measures in the form of medians and interquartile ranges (IQRs) were also used for 
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the analysis of non-parametric data. The software package GraphPad Prism 5 was 
used aid with data analysis. P<0.05 was considered as a statistically significant 
result.  
 
 
 
 
  
 
Sample Collection 
Epithelial cell separation and enrichment 
MACS Sorting 
 
2D cell culture  
Up to 3 days of cell cultivation 
 
(Healthy endometrium n=7; 
Endometriosis n=7) 
 
3D cell culture  
10-12 days of cell cultivation 
 
(Healthy endometrium n=3 pooled; 
Endometriosis n=3 pooled) 
 
qPCR 
 
Immunofluorscence 
(n=1) 
Statistical analysis 
(For non-parametric data) 
Figure 4.2 Flowchart to summarise the materials and methods 
RNA extraction and cDNA 
synthesis 
FACS Sorting 
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Chapter 3: Validation of Primers for use in qPCR 
3.1 Validating the Reference Gene 
Within each well, a single qPCR experiment measures the intensity of Sybr green 
fluorescence, which is proportionate to the amount of PCR product, and thus indicates 
gene expression levels within a certain sample, under specific experimental conditions. 
In order to increase the reliability of any relative qPCR experiment, an important step 
in gene expression analysis is the normalisation of the data to a reference gene. 
Normalisation helps to correct for any technical variation which may occur due to 
pipetting differences and also corrects for sample to sample variation in qPCR 
efficiency. The most frequently used approach is to normalise the mRNA level to an 
internal standard, also referred to as a reference or housekeeping gene which is 
assumed to display an equal level of expression in all cells within the control or 
experimental conditions under investigation. To achieve accurate quantification of 
mRNA levels, a suitable reference gene must be chosen which does not vary between 
the control and experimental conditions.  
 
Along with beta actin (ACTB) and 18s ribosomal RNA (18s rRNA), glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) is conventionally used and widely accepted as a 
housekeeping gene. Its role is vital within carbohydrate metabolism as this gene codes 
for the enzyme required to catalyse the sixth step of glycolysis (Selwood T, 2012). 
GAPDH is commonly used without validation of its suitability as a reference, and 
therefore it was for this reason that GAPDH was initially used whilst optimising the 
qPCR experiments within this study. With time, as the number of qPCR experiments 
that were being performed within this study increased, contamination within the 
GAPDH NTC appeared and gradually increased. Although individual components of 
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the qPCR experiment such as the nuclease-free water, the Taq polymerase and the 
GAPDH primer stock were changed, the contamination could not be eliminated, 
making the results unacceptable. This meant that an alternative reference gene had to 
be located before progressing to assess gene expression within the target samples.  
 
On exploration of the literature it was quickly discovered that although commonly 
used, GAPDH is no longer regarded as the most stable housekeeping gene and has 
been shown to vary considerably between different samples and tissue types (de 
Leeuw et al, 1989). It is likely that the changing physiological processes that occur 
throughout the menstrual cycle and the altered tissue environments within different 
gynaecological pathologies such as endometrial cancer or endometriosis, also have an 
effect on the expression levels of the housekeeping genes. Studies investigating 
placental gene expression at various stages of pregnancy have shown variable 
expression of the reference genes GAPDH and ACTB (Patel et al, 2002; Meller et al, 
2005). In addition, 18s and ACTB have been shown to display significant variation 
throughout the menstrual cycle (Sahlin, 1995; Ejskjaer et al, 2009). These studies led 
to further investigation and comparison of the stability of a range of housekeeping 
genes within the endometrium using GeNorm, a system used to select the best 
candidate reference gene. Sadek et al compared the stability of these genes within 
healthy endometrial tissue and tissue from women suffering from polycystic ovarian 
syndrome (PCOS) and found that out of nine reference genes, only YWHAZ, CYC1 and 
ACTB were stable within the experimental conditions. GAPDH was ranked as the 
worst housekeeping gene (Sadek et al, 2012). Vestergaard et al also explored the 
stability of housekeeping genes within eutopic and ectopic endometrium collected 
from women with endometriosis and healthy women. It was found that out of seven 
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reference genes, TBP and YWHAZ were ranked the best pair using GeNorm analysis 
and that YWHAZ was the single most stable gene using NormFinder analysis 
(Vestergaard et al, 2011). It was following this literature search that YWHAZ was 
considered as a suitable housekeeping gene to explore and test under our experimental 
conditions. Tyrosine 3-monooxygenase also known as YWHAZ, is a gene which 
belongs to the 14-3-3 family of proteins and acts to mediate cell-cell signal 
transduction by binding to phosphoserine-containing proteins (NCBI, 2012).  
 
In order to confirm that YWHAZ would be a reliable housekeeping gene, its variability 
was compared to the more widely accepted and accredited ACTB on some of the 
normal endometrial samples which were collected for this project. Its stability was also 
investigated on endometrial tissue collected from a female with endometriosis to assess 
whether it was stable within the target pathology within this study. The histogram in 
figure 4.3 shows the cycle differences or ∆Ct values between YWHAZ and ACTB when 
their gene expression was measured within the normal SSEA-1 MACS sorted 
endometrial samples, collected for the purpose of this study. It can be seen here that 
there was minimal variation in the ∆Ct values between ACTB and YWHAZ (average 
∆Ct value of 4.34), proving the stability of YWHAZ amongst the study samples (figure 
4.3).  
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The following quantification curve illustrates that YWHAZ does not vary in patients 
with endometriosis also when compared to ACTB (figure 4.4).  
 
 
 
 
 
 
 
 
 
The cycle difference between YWHAZ and ACTB was found to be 4.18 cycles within 
full thickness normal endometrial tissue (represented by the red arrow) at a threshold 
of 0.07. Within eutopic endometrial tissue taken from a patient with endometriosis the 
cycle difference between ACTB and YWHAZ was found to be 3.92 cycles at the same 
threshold. These results prove that there was around a 4 cycle difference in gene 
expression between the two reference genes, and this did not vary within 
endometriosis. It could therefore be concluded that the expression of YWHAZ is stable 
within endometriosis. 
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3.2 Validation of Specific Primers 
3.2.1 human telomerase reverse transcriptase (hTERT) 
hTERT was initially included as one of the target genes to study within the SSEA-1 
sorted cells. However, it quickly became evident that hTERT mRNA was present at 
very low levels within the sorted cells and generating quantifiable results via qPCR 
proved extremely difficult. Three different primer sequences for human specific TERT 
were already available within the lab. The sequences for these are shown below (table 
12): 
Table 12 hTERT primer pair sequences (Pairs 1-3) 
Gene Sequence Product 
Size 
Reference 
TERT 1 F: 5’CCGCCTGAGCTGTACTTTGT3’ 
R: 5’CAGGTGAGCCACGAACTGT3’ 
234 Rahmati-
Yamchi M, 
2011 
TERT 2 F: 5’AGGGGCAAGTCCTACGTCCAGT3’ 
R:5’CACCAACAAGAAATCATCCACC3’ 
159 Meeran 
SM, 2010 
TERT 3 F: 5’CGTACAGGTTTCACGCATGTG3’ 
R: 5’ATGACGCGCAGGAAAAATG3’ 
82 Lehner R, 
2002 
 
To select the best primer pair, qPCR was performed using all three primer sets on a 
range of different positive control templates, including endometrial cancer, Hues7 
ESCs and full thickness endometrium taken during the proliferative phase. The 
amplification products were run on an agarose gel and the following results were 
generated (figure 4.5). 
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It can be seen from the gel above that TERT 1 gave rise to multiple product bands 
within endometrial cancer 14 tissue. TERT 1 and TERT 2 both failed to detect 
expression within the Hues7 ESCs. TERT3 showed a consistent single band within all 
three sample types and therefore it was concluded that this was the best primer pair to 
use. TERT 3 had also been used successfully by Dean Hallam, in our partner lab within 
Newcastle, who had optimised this primer on corneal tissue at an annealing 
temperature of 55
o
C. This annealing temperature was therefore adopted for the 
endometrial samples within this study, but quantifiable results could not be achieved 
due to low expression levels within these samples. Although an attempt to optimise the 
TERT 3 primer set was made, this failed to provide quantifiable qPCR results. A 
literature search was performed and a fourth primer set, TERT 4, was discovered which 
had been used by Kim CM et al for qPCR on endometrial tissue taken from normal 
healthy women, and women with endometriosis (table 13) (Kim et al, 2007). As this 
primer set had proven successful on the same tissue used in our study, it was decided 
to run this under the same conditions on serial dilutions of a HeLa cell positive control, 
in order to construct a standard curve (figure 4.5). 
 
Table 13 hTERT primer pair sequences (Pair 4) 
Gene Sequence Product 
Size 
Reference 
TERT 4 F: 5’TGACACCTCACCTCACCCAC3’ 
R: 5’CACTGTCTTCCGCAAGTTCAC3’ 
95 Kim CM, 
2007 
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Following this, the primer set was run on the sorted samples. Unfortunately 
quantifiable results again could not be achieved via qPCR when using this primer set. 
Instead, qualitative analysis was performed by running the PCR products on an 
agarose gel. The gel showed the expression of hTERT in both the SSEA-1
+
 and SSEA-
1
-
 fractions. Comparing the intensity of the hTERT bands to YWHAZ, there appeared to 
be equal levels of hTERT in both cell populations in the majority of samples (samples 
1, 4, 5 and 6). Samples 2 and 3 both seemed to express hTERT within the SSEA-1
-
 
cells only, whereas sample 7 looked to have more hTERT within the SSEA-1
+
 
population (see figure 4.7 below).  
 
hTERT was ultimately excluded from any further qPCR experiments on additional 
samples, all of which had relatively low quantities of RNA. 
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It has been reported within the literature that techniques such as microdissection and 
immunomagnetic bead separation, used to enrich for a target cell population,  make the 
detection of hTERT mRNA difficult (Lehner M, 2002). Methods of detection of 
hTERT transcripts within these samples are still not well established. The hTERT 
transcript has at least six alternative splice variants, including four insertions and two 
deletions (Lehner et al, 2002). The four insertion variants and the β-deletion variant all 
result in the premature termination of the translation of hTERT (Lehner et al, 2002). 
On the other hand, the α-deletion variant is a powerful inhibitor of telomerase 
expression and activity (Lehner et al, 2002). As telomerase protein is observed by IHC 
and telomerase activity is detected within the endometrial epithelium and SSEA-1 
sorted cells, it seems that it was purely the low concentrations of hTERT mRNA rather 
than alternative splicing which made qPCR on these samples difficult and imprecise 
(Hapangama et al, 2008; Hapangama et al, 2009; Tanaka et al, 1998; Hapangama et al, 
unpublished results). It is also possible that in some samples, the low levels of hTERT 
may have been due to mRNA degradation. For accurate quantification of samples 
containing lower concentrations, the use of digital PCR may be considered, or the 
mRNA could be amplified prior to reverse transcriptase (Bustin et al, 2009). 
 
3.2.2 leucine-rich repeat containing G protein-coupled receptor 5 (LGR5) 
The human endometrium resembles the gastrointestinal system with its rapid turnover 
time, highly regenerative capacity and glandular components. It was for these reasons 
that LGR5 was initially included in the preliminary investigations of this study, to 
establish whether it also expressed in endometrial epithelial cells. The LGR5 qPCR 
primer sequences which had been selected from a previous publication were already 
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found available within the lab when starting this project. The sequence has been 
indicated in the following table (table 14). 
 
Table 14 LGR5 primer pair sequences 
Gene Sequence Product 
Size 
Reference 
LGR5 F: 5’CTTCCAACCTCAGCGTCTTC3’ 
R: 5’TTTCCCGCAAGACGTAACTC3’ 
118 Walker et 
al, 2011 
 
This primer was initially tested on the human colon adenocarcinoma cell line HT29, as 
a positive control, and the following standard curve was generated (figures 4.8 and 
4.9).  
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It is evident from the graphs above that these primers gave rise to a large amount of 
unspecific primer-dimer product. When testing this primer set on the full thickness 
endometrium, very low levels of specific product were detected. Increasing the 
annealing temperature from 55
o
C to 60
o
C did not help to improve the specificity or 
efficiency of these primers (figure 5.0). 
 
When proceeding to test the primer set on sorted stomal and epithelial endometrial 
cells, it became evident that LGR5 was only expressed by the stromal cell population 
and not by endometrial epithelial cells (figure 5.1). As this study focuses on 
endometrial epithelial cells alone, LGR5 was excluded from the study and its 
expression was not investigated within the SSEA-1 sorted epithelial cells. 
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3.2.3 Oestrogen receptor beta (ERβ) 
The action of oestrogen is modulated by two subtypes of oestrogen receptor, known as 
oestrogen receptor alpha (ERα) and oestrogen receptor beta (ERβ). Therefore it was 
initially planned that the expression of both of these receptors would be investigated 
within the SSEA-1 sorted endometrial epithelial cells. An ERβ primer set suitable for 
qPCR was selected from within the literature and has been identified within the table 
below (table 15). The authors of this paper are established experts in the study of ERβ.  
 
Table 15 ERβ1 primer pair sequences 
Gene Sequence Product 
Size 
Reference 
ERβ1 F: 5’CCTGGCTAACCTCCTGATGCT3’ 
R: 5’ CCACATTTTTGCACTTCATGTTG 3’ 
92 Critchley 
et al, 2009 
 
Critchley et al and others have reported that the level of ERβ mRNA is low within the 
endometrium (Critchley et al, 2009). Brandenberger et al established that ERα is 15 
times more abundant that ERβ within normal endometrial stromal cells (Brandenberger 
et al, 1999). ERβ mRNA is expressed at significantly higher levels within the late 
secretory phase compared to any other time in the cycle. Studies by Critchley et al 
however have shown that the mRNA and protein levels for ERβ within the 
endometrium do not necessarily correlate. They found significant amounts of this 
nuclear protein within the tissue but low levels of mRNA, which was found to be in 
keeping with our findings (Critchley et al, 2009).  
 
When testing the primers mentioned above on serial dilutions of a full thickness 
endometrial sample taken from the secretory phase, the following standard curve was 
generated (figures 5.2 and 5.3).  
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qPCR on the secretory phase endometrium (positive control) proved that ERβ mRNA 
is present at a very low level within the endometrium. For this reason, ERβ qPCR was 
not pursued on the sorted samples as concentrations would be significantly lower than 
the whole tissue samples. In contrast to the low mRNA levels, the following IHC 
images of the normal endometrium show that the ERβ protein is present in abundance 
(figure 5.4). This is consistent with the findings of previous studies (Critchley et al, 
2009). 
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Chapter 4: Results 
4.1 Patient Demographics 
 
This study took place over a 12 month period, from the beginning of September 2011 
until the end of August 2012. Over the entire duration of the study, samples collected 
from a total of 23 participants who were recruited for the study (reference 
09/H1005/55 and 04/Q1505/112) were analysed. This included 14 normal fertile 
women who served as controls and 9 women with endometriosis. Of these, 2 control 
patients were excluded from the data analysis due to the exceedingly low and degraded 
RNA yields making them not suitable for analysis.  
 
Patient Demographics: 
Note that the 2 patients who were excluded from the data analyses have not been 
included in the table below. 
 
Table 16 Demographic data for all patients included in the study 
 
 Control Group 
(n=12) 
Endometriosis Group 
(n=8) 
Sample Type 
(no. patients) 
Pipelle: 7 
Full thickness: 5 
Pipelle: 5 
Full thickness: 3 
Age (years) Median: 40.5 
Range: 30-49 
Median: 39 
Range:27-48 
Weight (kg) Median: 76 
Range: 56-111 
Median: 70 
Range: 52-103 
Height (m) Median: 1.605 
Range: 1.51-1.84 
Median: 1.635 
Range: 1.55-1.71 
BMI Median: 29.55 
Range: 24.5-39.8 
Median: 25.25 
Range: 20.5-37.8 
Parity Median: 2 
Range: 0-4 
Median: 1 
Range: 0-4 
Gravidity Median: 2 
Range: 0-4 
Median: 1 
Range: 0-4 
Cycle Stage 
(no. patients) 
Proliferative:4         Secretory:5 
(Missing data) 
Mid-cycle:3              Secretory:5 
Endometriosis 
Stage (no. 
patients) 
Not Applicable Stage 1: 2                Stage 3: 0 
Stage 2: 1                  Stage 4: 4 
(Missing data) 
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A couple of patient demographic details were missing from this data set and are 
currently being located (missing data indicated in the table above). In order to assess 
whether there were any statistical differences in patient demographics at baseline 
between the control group (with normal endometrial tissue) and patients with 
endometriosis, statistical analysis has been conducted. This is important as if baseline 
differences between patient groups are not accounted and adjusted for, direct 
comparison between the two groups may be invalid. Due to the low number of patients 
within each group, non-parametric statistical tests were used to analyse our data 
throughout this study.  Using the MWU test for nonparametric independent groups, it 
was confirmed that there were no statistical differences (p > 0.05) between any of the 
demographic variables documented in the table above. Direct comparison between the 
control and pathological groups was therefore valid and no adjustments were needed at 
baseline. 
Table 17: P-values for demographic variables between groups; MWU test  
Demographic Variable P-value 
Age 0.9692 
Weight 0.1888 
Height 0.7669 
BMI 0.0698 
Parity 0.1752 
Gravidity 0.113 
 
From one patient who was recruited into the study, multiple samples could be taken for 
use in several lab experiments and techniques. From the 21 patients mentioned 
previously, 14 samples were MACS sorted (7 normal endometrium, 7 endometriosis), 
3 were FACS sorted (all normal endometrium), 6 were grown into organoids in 3D 
culture (3 normal endometrium, 3 endometriosis) and 1 was used for IF staining 
(normal endometrium).  
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4.2 mRNA Data: SSEA-1
+
 versus SSEA-1
-
 Endometrial Epithelial 
Cell Population  
qPCR was used to compare the mRNA levels of the stem cell markers OCT4, NANOG, 
SOX2, CD133 and PODXL within the SSEA-1 sorted epithelial cells taken from the 
normal endometrium. The expression of markers of differentiation, PR and ERα, and 
the epithelial cell marker, CD9, were also analysed within these samples. FUT4 was 
included in the gene expression profile of these samples as its function is said to 
include the fucosylation of the carbohydrate structure SSEA-1 (Ponnampalam et al, 
2008) hence may be a surrogate marker for SSEA-1. As SSEA-1 is a carbohydrate, it 
could not be looked at directly using qPCR. 
 
4.2.1 MACS Sorted Normal Endometrium (n=7) 
 
Seven samples were MACS sorted to generate an SSEA-1
+
 and an SSEA-1
-
 epithelial 
cell population for each sample. The presence of all genes was confirmed within both 
SSEA-1 MACS sorted fractions for all samples, excluding SOX2 (figure 5.5). SOX2 
was found to be absent across all samples. This was consistent with IHC analysis of 
full thickness endometrial tissue sections performed at Liverpool Women’s Hospital 
laboratory, which did not find the SOX2 protein anywhere within the normal full 
thickness endometrium (figure 5.6). The absence of SOX2 within the endometrium was 
also supported by the negative qPCR results on non-sorted normal full thickness 
endometrium. 
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When comparing quantitative data for the genes expressed above in the normal 
endometrium, no significant differences were seen between the expression levels of the 
stem cell markers OCT4, NANOG, PODXL and CD133 in the SSEA-1
+
 and the SSEA-
1
-
 epithelial cell fractions.  Of these stem cell markers, PODXL mRNA was most 
highly expressed by the sorted samples with a median relative expression level of 0.26 
and 0.4 (WSR test; p=0.8125) in the SSEA-1
+
 and SSEA-1
-
 fractions respectively. 
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OCT4 mRNA was also highly expressed by both fractions with median relative 
expression levels of 0.2 within both populations (WSR test; p=0.2188). Comparably, 
CD133 and NANOG were both expressed to a lower degree by both fractions with 
median relative expression levels of 0.01-0.02 (WSR test; p=0.8125) and 1.0x10
-4
 
(WSR test; p=0.2188) respectively (see results in figure 5.7). 
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For markers of differentiation, the expression of ERα and PR mRNA were both 
significantly greater within the SSEA-1
-
 epithelial fraction (WSR test; p=0.0156). For 
ERα and PR, expression was approximately 3-fold and 5-fold greater respectively 
within the SSEA-1
-
 population (see results in figure 5.8). 
 
 
 
For other markers, CD9 and FUT4, no significant differences in expression levels were 
noted between the SSEA-1 sorted populations (WSR test; p=0.9375) (see results in 
figure 5.9). 
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4.2.2 MACS Sorted Endometriosis Samples (n=7) 
 
qPCR on seven MACS sorted samples taken from women with endometriosis showed 
similar mRNA results between the SSEA-1
+
 and SSEA-1
- 
epithelial cell populations as 
seen in the normal endometrium. All samples expressed all genes except for SOX2, 
which again was absent within the pathological endometrium. For stem markers 
OCT4, NANOG, CD133 and PODXL, again there were no significant differences in 
expression between the SSEA-1 MACS sorted populations. Median relative expression 
of PODXL was the highest, with levels of 0.59 and 0.73 within the SSEA-1
+
 and 
SSEA-1
-
 populations respectively (WSR test; p=0.4688). OCT4 expression was also 
relatively high at median levels of 0.42 and 0.75 within the SSEA-1
+ 
and SSEA-1
-
 
populations respectively (WSR test; p=2969). For CD133 and NANOG relative 
expression was again seen at lower levels (see results in figure 6.0). 
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For markers of differentiation, PR showed similar results to those found in the normal 
endometrium. A statistically significant 2-fold increase (WSR test; p=0.0156) in PR 
mRNA expression was found within the SSEA-1
-
 epithelial cell population when 
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compared to the SSEA-1
+
 population. Unlike the normal endometrium however, no 
significant difference in ERα expression was noted between the sorted populations 
although expression was still 1.7-fold higher in the SSEA-1
-
 population (see figure 
6.1). 
 
 
Similar to the results found within the normal fertile endometrium, CD9 and FUT4, 
were both expressed at equal levels within endometrial epithelial cells sorted according 
to the expression of SSEA-1 taken from women with endometriosis. FUT4 showed a 
median expression level of 0.18 in both sorted fractions (WSR test; p=0.4688) (see 
figure 6.2). 
 
 
 
 
 
 
 
109 
 
 
 
 
4.2.3 FACS Sorted Normal Endometrium (n=3) 
  
As MACS sorting only achieves up to 70-75% enrichment of SSEA-1 in the SSEA-1
+
 
fraction, the accuracy of the qPCR results may have been affected by contaminating 
SSEA-1+ cells and stromal cells which may have remained within the SSEA-1
 
depleted cell fraction. This may have had a significant effect on the results, especially 
if the contaminating cells were stromal stem cells or SSEA-1
+ 
epithelial cells. It was 
therefore important to verify whether any true differences in gene expression seen 
between pure SSEA-1
+
 and SSEA-1
-
 cell populations had been masked/exaggerated in 
the previous results by repeating the qPCR experiments on FACS sorted normal 
endometrial samples. FACS sorting for both SSEA-1+ and the epithelial marker 
CD9+, is over 90% efficient in picking up cells that express both SSEA-1 and CD9 
therefore are more likely to be epithelial cells that express SSEA-1. We believe, 
therefore qPCR results achieved from these samples are a more accurate 
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representation.  Unfortunately only a limited number of normal endometrial samples 
could be sorted using FACS throughout the duration of this project due to technical 
difficulties (the inaccessibility of the FACS machine) and the requirement for a high 
cell yield. A representative FACS profile of the sorted epithelial cells is shown in 
figure 6.3 below. 
 
 
 
Gene expression analysis on three FACS sorted normal endometrial samples 
confirmed that there were no differences in the mRNA levels of OCT4, NANOG, 
PODXL, CD133, CD9 and FUT4 between the SSEA-1
+
/CD9+ and SSEA-1
-
/CD9- cell 
populations. Although statistical significance was not achieved, potentially due to the 
low number of samples/cells, unlike the results obtained with MACS, a 2-fold greater 
level of NANOG mRNA expression was seen within the FACS-sorted SSEA-1
+
/CD9+ 
population compared to the SSEA-1
-
/CD9-  population. Contrary to the previous 
results, data also showed that there were no differences in the expression levels of the 
differentiation markers ERα and PR, although there was still a 3.7 and 2-fold greater 
111 
 
expression of these genes respectively within the SSEA-1
-
 fraction (see figures 6.4 and 
6.4 continued). 
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4.3 mRNA Data: Comparison of Gene Expression within SSEA-1
+ 
Endometrial Epithelial Cells taken from Healthy Women and 
Women with Endometriosis  
As it is postulated that the epithelial SPC resides within the SSEA-1
+
 epithelial cell 
fraction, and that abnormal stem cells are implicated in the pathogenesis of 
endometriosis, we progressed to compare the SSEA-1
+
 populations between normal 
and pathological samples.  
 
Direct comparisons between the mRNA levels for the particular genes under 
investigation within this study indicated an increase in expression of the stem cell 
markers OCT4, NANOG and PODXL within the eutopic endometriosis samples 
compared to those taken from healthy, fertile patients. This reached significance for 
markers OCT4 (WSR test; p=0.0469) and NANOG (WSR test; p=0.0313) with a 2 and 
3.4-fold increase respectively in mRNA levels within the endometriosis samples. 
PODXL showed a 2.3 fold increase within the endometriosis samples, although not 
significant. CD133 levels show no difference between the two groups (see figure 6.5). 
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Markers of differentiation showed no significant differences between the expression of 
ERα and PR mRNA within endometriosis or normal endometrial tissue (see figure 
6.6). 
 
 
 
A significant (WSR test; p=0.0469) 2.6-fold increase in FUT4 expression was seen 
within endometriosis samples compared to the normal samples. CD9 mRNA 
expression was only slightly increased in endometriosis samples (see figure 6.7). 
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4.4 mRNA Data: Normal and endometriosis SSEA-1 sorted epithelial 
cells grown in 3D culture (organoids) 
 
SSEA-1 sorted epithelial cells have been shown to form gland-like structures (which 
we called as spheroids/organoids) in 3D culture, and they have structural similarities to 
the endometrial glands seen in vivo. These organoids arise primarily from the MACS 
sorted SSEA-1
+
 epithelial fraction, with significantly fewer and smaller organoids 
being formed by the SSEA-1
- 
cell population. 2D culture has many limitations when 
studying endometrial cells, and the morphology of the cells seems to be very different 
to those seen in vivo. The Matrigel acts as an ECM which imitates the architecture of 
the normal human endometrium, and may help to preserve the stemness of any SPCs 
which may be contained within the cell population on the one hand; and also may 
allow differentiation of the cells to create an endometrium like environment hence 
provide a stem cell niche to contain a stem cell (Zhu et al, 2012).  
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Organoids, made up of clusters of a small number of cells, gave rise to low RNA 
yields. This made the accurate study of genes that do not show high mRNA expression 
levels, such as stem cell markers, via qPCR very difficult. For this reason, organoids 
grown from SSEA-1 sorted cells were pooled from three patients to achieve a higher 
RNA concentration. Unfortunately, this meant that statistical analysis of this data was 
not possible. qPCR was performed on the  gene panel previously mentioned on two 
SSEA-1 sorted samples, one pooled from three patients with a normal endometrium 
and the second  pooled from three patients with endometriosis. 
 
The qPCR results obtained from these samples were different from those obtained 
from the 2D-cultured samples. In 3D-culture, the stem cell markers OCT4, NANOG, 
PODXL and CD133, were seen to be raised within the SSEA-1
+
 organoids when 
compared to the SSEA-1
-
 organoids. The difference between the sorted populations 
was even more pronounced within women with endometriosis, with expression greatly 
increased for most of these genes within the SSEA-1
+
 organoids (see figure 6.8).  
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Equal levels of ERα mRNA expression were measured in the SSEA-1+ and SSEA-1- 
organoids grown from normal endometrium. However, when organoids were grown 
from cells taken from women with endometriosis, a large increase in ERα expression 
was clearly seen within the SSEA-1
+ 
organoids. Similar differences in PR expression 
was seen between SSEA-1
+
 and SSEA-1
-
 organoids grown from the normal and 
endometriosis endometrium. When comparing the SSEA-1
+
 cells to SSEA-1
- 
population, the cells did not show a difference in PR mRNA expression after growth in 
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3D culture. This was in contrast to the significant up-regulation previously seen in the 
SSEA-1
-
 fraction when grown in 2D culture (see figure 6.9).  
 
 
 
Like the stem cell markers, the expression of FUT4 was seen to increase in the SSEA-
1
+
 cells taken from the endometriosis patients in comparison to the SSEA-1
+
 cells 
grown from normal women in 3D culture.  The difference between the expression of 
CD9 in the SSEA-1
+
 and SSEA-1
-
 cells grown in 3D culture appeared to be more 
pronounced in the endometriosis group, but there was no obvious difference between 
the SSEA-1
+ 
organoids between healthy and endometriosis groups in CD9 expression. 
The difference in the expression of FUT4 between the SSEA-1
+
 and SSEA-1
-
 
organoids was also more pronounced in endometriosis (see figure 7.0). 
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4.5 Protein Analysis: Immunofluorescence (IF) 
 
In order to see if an increase/decrease in mRNA levels of a particular target gene led 
to a noticeable increase/decrease in protein expression, IF staining was performed on 
the SSEA-1 MACS sorted normal epithelial cells plated onto 8-well chamber slides. 
However, the level of mRNA and the level of protein do not necessarily correlate 
(Gygi et al, 1999; Anderson et al, 1997). The images shown below represent IF 
staining for SSEA-1 within the MACS sorted SSEA-1
-
 and SSEA-1
+
 epithelial cell 
populations, and verify that there is depletion and enrichment for SSEA-1 in the 
respective fractions (figure 7.1). 
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One normal endometrial sample was mechanically and enzymatically digested, 
crudely sorted in to epithelial and stromal cells, and the epithelial fraction was grown 
in 2D culture for 5 days. The cells were then trypsinised, singly dispersed and MACS 
sorted on the expression of SSEA-1 in to SSEA-1
+ 
or SSEA-1
-
 cells and both were 
plated on chamber slides for staining. Dual labelling was used to stain for cytokeratin 
(green fluorescence) and the protein of interest (red fluorescence). As DAPI was also 
used to stain the nuclei blue, any target nuclear proteins that were present were seen 
in pink due to the co-localisation of colours.  
 
The protein for OCT4 and NANOG was seen within both SSEA-1 populations, 
although the OCT4 protein was seen at extremely low levels in only a few cells. This 
conflicted with qPCR data as unlike the protein, NANOG mRNA was consistently 
seen at a much lower level than OCT4. However, caution should be taken when 
comparing the expression levels of different genes with qPCR, as any differences in 
Ct values may be due to variations in primer efficiency rather than differences in 
gene transcription. In addition, nuclear staining patterns for these transcription 
factors appeared different to those seen in the human ESC positive controls, staining 
only part of the nucleus within the sorted cells rather than throughout the nucleus like 
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the ESCs. Surprisingly PR and PODXL proteins were not found at all in either the 
SSEA-1 MACS sorted populations. The telomerase protein, unlike the hTERT 
mRNA, was present in many cells within both SSEA-1 sorted populations. This 
result correlates with previous telomerase activity data on these cells, and may 
highlight the difficulties of hTERT qPCR (Valentijn et al, 2013). The results 
confirmed the presence of ERα and ERβ protein in abundance in both SSEA-1 
populations. This was in agreement with previous literature which has stated that 
although the ERβ protein is commonly seen, the mRNA is lowly expressed and does 
not correlate to the protein (Critchley et al, 2009) (see figures 7.2, 7.3, 7.4 and 7.4 
continued below). 
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As the CD133 antibody that had previously been optimised within our laboratory had 
been discontinued, no CD133 antibody was available within our laboratory to test on 
the SSEA-1 sorted cells within the time available. An image of IHC staining for 
CD133 using the previous antibody has been included below to show the presence of 
this protein within endometrial cancer tissue (see figure 7.5). 
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Chapter 5: Discussion 
This was primarily a study examining the transcriptional profile of a selected set of 
genes in a sorted and isolated sub population of endometrial epithelial cells. The 
primary endometrial epithelial cells sorted on the expression of SSEA-1 are expected 
to contain a SPC population;
 
therefore we evaluate the expression of genes that are 
associated with stem cell activity and an undifferentiated state. In order to further 
confirm that the SSEA-1
+ 
endometrial epithelial cells indeed have specific SPC 
activity, their gene expression profile for the same genes was compared to that of the 
SSEA-1
-
 endometrial epithelial population, which represented more 
differentiated/mature epithelial cells from the endometrium. We studied the cells, 
cultured in both 2D and 3D culture systems to identify whether either of those 
conditions would favour the maintenance of an undifferentiated status. The gene 
expression profile of SSEA-1
+
 cells was also compared in the cells derived from the 
endometrium of women with and without endometriosis to assess whether we could 
identify if they might play a role in the pathogenesis of this disease. IF staining of 
MACS sorted SSEA-1 epithelial cells was also used to see if any differences in gene 
expression also correlated with similar differences in the protein levels.   
 
5.1 Normal Control Group 
Our results confirmed the expression of human genes OCT4, NANOG, PODXL, 
CD133, ERα, ERβ, PR, CD9 and FUT4 across all samples included in our study, both 
SSEA-1
+
 and SSEA-1
- 
cell fractions. These results confirm that there is stem cell 
activity within the endometrial epithelial cell population, and supports the hypothesis 
that there may be cells with SPC activity in both epithelial and stromal fractions of the 
endometrium. SOX2 mRNA was not detected within the full thickness endometrium or 
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either SSEA-1 epithelial cell fraction within any of the samples. Agreeing with this 
observation, the protein was also not visualised within the full thickness endometrium 
using IHC. This is consistent with the previous findings of Forte et al who analysed the 
expression profile of 13 genes, including SOX2, on non-sorted normal endometrial and 
endometriotic tissue using reverse transcription PCR. He found that SOX2 expression 
was absent across all 14 endometrial tissue and 12 endometriotic tissues, within all 
phases of the menstrual cycle and all stages of endometriosis. The lack of SOX2 may 
not be surprising, as although it may be needed for pluripotency in human ESCs, this is 
not an essential feature of ASCs and is unlikely to be necessary for the endometrial 
SPC (Forte et al, 2009). Unlike in the mouse ESCs, the key function of SOX2 in 
human ESC has been described within the literature as largely dispensable compared 
to the other primitive pluripotency genes OCT4 and NANOG, which are essential for 
the maintenance of human ESC self-renewal. Furthermore, evidence from induced 
pluripotent stem (iPS) cells suggest that the function of all these embryonic markers 
are rather different in human cells when compared to the mouse cells, and propose that 
the three pluripotency genes work independently to prevent differentiation along a 
specific lineage (Wang et al, 2012). SOX2 and SOX3 both repress mesendodermal 
differentiation, but the knock-down of SOX2 within human ESCs does not seem to 
alter the pluripotent profile. This may be due to the compensatory action of SOX3 
which is up-regulated when SOX2 levels are low, maintaining pluripotency within 
human ESCs (Wang et al, 2012).   
 
Within the normal MACS sorted SSEA-1
+
 cells grown in 2D culture, no significant 
differences in stem cell gene expression was seen between the SSEA-1
+
 or SSEA-1
-
 
cells. This was evident in both MACS and FACS sorted samples, suggesting that both 
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populations possess cells expressing stem cell-specific genes. There are a number of 
possibilities which may account for these results.  As MACS and FACS sorting are not 
100% pure, any true differences in expression may have been masked by 
contamination of stromal stem cells or SSEA-1
+
 epithelial cells within the SSEA-1
- 
cell 
population. However, as FACS sorting has greater than 90% efficiency and the results 
from these samples support those seen from the MACS sorted samples, it is more 
likely that these results are a true reflection of gene expression profile within the 
populations studied. If SSEA-1
+
 cells are largely a progenitor cell population, it is 
possible that a very small, more primitive stem cell sub-population is included within 
both SSEA-1
+/-
 fractions. 
  
In mouse ESCs, OCT4, NANOG and SOX2 genes play a core regulatory function in 
maintaining pluripotency, however in human ESC, they may play a different role 
depending on their levels and the presence of other factors. For example, at high levels 
OCT4 facilitates self-renewal only when BMP4 is absent but specify mesendoderm in 
the presence of BMP4. Conversely, low levels of OCT4 induce embryonic ectoderm 
differentiation in the absence of BMP4 but specify extraembryonic lineages in the 
presence of BMP4. NANOG represses embryonic ectoderm differentiation but has little 
effect on other lineages, whereas SOX2 and SOX3 are redundant and repress 
mesendoderm differentiation. We have not studied the existence of BMP4 in our cells. 
There are no conclusive reports on the BMP4 expression in SSEA-1 expressing human 
endometrial glandular epithelium, and the existing single paper on BMP4 expression in 
human endometrium only shows that in the secretory phase, endometrial epithelium 
does not express BMP4 but stromal cells do (Wang et al, 2012; Stoikos et al, 2008). 
Therefore, we are unable to comment on the particular function of the expression of 
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these transcription factors in our cells. However, we can suggest that at the low levels 
of OCT4 expression observed in endometrial epithelial cells in vitro, merely suggest 
epithelial differentiation of these cells.  Another explanation may be the 2D culture 
system in which the sorted epithelial cells were grown, does not favour stemness but 
drives cells towards differentiation. Whilst traditional 2D culture may be sufficient to 
study the biological functions of endometrial cells, it has many limitations. When 
grown in 2D culture, endometrial cells lose their typical epithelial 
architectural/structural characteristics and their morphology from what is seen in vivo, 
and they no longer maintain their columnar shape and intercellular junctions, but 
become flat and lose their polarity. This may mean that the transcriptional stem cell 
profiles studied on the MACS and FACS sorted cells grown in 2D culture, may not be 
a true representation of the expression levels seen in vivo (Hai-yan et al, 2012). 
 
We aimed to overcome this problem with the use of a 3D culture model; a system 
which is well recognised as the optimal method of studying endometrial epithelial 
cells in vitro (Hai-yan et al, 2012; Eritja et al, 2010; Bläuer et al, 2008). Matrigel is a 
gelatinous protein mixture urea extract derived from the basal lamina-rich mouse 
Engelbreth-Holm-Swarm (EHS) tumour. It is an ideal substrate for functional cells in 
in vitro as it reconstitutes the natural basal lamina and mimics the ECM within tissues 
in vivo (Hai-yan et al, 2012). 3D culture models using epithelial cells were first 
established using collagen-based matrices. However more recently, developments 
using breast epithelial cell lines have shown that cultures derived from EHS tumours 
are first choice for the growth of glandular epithelial tissues. This model retains 
structural polarity, epithelial cell morphology and is essential to imitate the 
architecture of the normal human endometrium in vivo. Nevertheless, although 
Matrigel is necessary for cellular polarity and glandular formation, it does not 
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support glandular growth and proliferation. Additional supplements including 
epithelial EGF and ITS are required for the development of glandular structures, and 
therefore these were used within this study (Hai-yan et al, 2012; Eritja et al, 2010). 
Our data on gene expression from SSEA-1 sorted epithelial cells growth in 3D 
culture (or organoids), showed a clear difference from those grown on a 2D culture 
system, with an obvious up-regulation of all stem cell markers within the SSEA-1
+
 
organoids compared to the SSEA-1
-
 organoids taken from the normal endometrium. 
This provides further evidence to support that the 3D culture system may be 
recapitulating the natural stem cell niche within the endometrium in vivo, hence 
preserving stemness of an endometrial stem cells and preventing differentiation of 
the SSEA-1
+ 
population. It is therefore more likely that the gene expression profile 
obtained from these gland-like structures is a more accurate representation of the 
levels that would be expressed from these cells within their natural 
microenvironment.  
 
Expression levels of OCT4 and FUT4 mRNA were the highest of all genes 
throughout the study. OCT4 consistently showed a level of expression considerably 
higher (approximately 1000 times higher) than that of its fellow transcription factor, 
NANOG. If the function of these markers is self-renewal and pluripotency as seen in 
ESCs, and with a similar function to NANOG, it was not anticipated that the signal 
level of OCT4 would be so high in comparison within our adult tissue. Many papers 
are now being published stating that results of OCT4 expression need to be 
interpreted with caution and much controversy has arisen over its existence within 
somatic cells (Lengner et al, 2008; Liedtke et al, 2008; Zangrossi et al, 2007; Seo et 
al, 2009). Although further evidence is now emerging to describe potential problems 
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when dealing with OCT4, many authors still have no knowledge of the recent 
discovery that two main variants of OCT4 exist as a consequence of alternate 
splicing; OCT4A and OCT4B (also to referred to as splice variants 1 and 2. On a 
nucleotide level, both isoforms are identical from exon 2 through to exon 5. The 
genetic difference between the two variants arises from exon 1, which is missing 
from the OCT4B transcript and instead is replaced by 202 bps from the intron 1-2 
region. Although similar in structure, the two variants have very different functions 
(Liedtke S, 2008). Unlike OCT4A, OCT4B has no function in regulating self renewal 
and cannot sustain stem cell properties (Seo et al, 2009). With IHC, OCT4B gives 
rise to staining within the cytoplasmic compartment, unlike OCT4A which is nuclear, 
raising question as to if OCT4B has any function as a transcription factor (Liedtke et 
al, 2008). In addition to these splice variants, at least 6 pseudogenes and other OCT4-
like sequences, which are highly homologous for OCT4A exist. These account for yet 
more sources of potential difficulties in interpretation of the results. It is therefore 
crucial to verify that a primer set is OCT4A specific and discriminates this variant 
from other splice variants and pseudogenes to provide reliable mRNA data (Liedtke 
et al, 2008; Zangrossi et al, 2007). When entering our OCT4 primer sequences into 
the Basic Local Alignment Search Tool (BLAST), it became evident that our primers 
are homologous with multiple splice variants and OCT4-like sequences (in addition 
to variants 1 and 2) and also  pseudogenes 3 and 4. This may account for the high 
expression levels of OCT4 seen within this study and so results should be interpreted 
with caution. Nevertheless, although not all of the OCT4 signal may represent 
pluripotency or self-renewal, lower levels of OCT4A are still expressed by both 
SSEA-1 populations. Our OCT4 primers were verified using Hues7 ESCs which 
displayed the same melting point and product size following qPCR and gel 
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electrophoresis as those seen within our sorted epithelial samples. In addition, IF 
staining using an OCT4A specific antibody showed positive staining in part of the 
nucleus, although at much low level and in far fewer cells when compared to the 
positive control of ESCs. This verifies that some of the SSEA-1 expressing epithelial 
cells do express OCT4 and those cells may have SPC activity.  
 
As SSEA-1 is a carbohydrate and therefore cannot be investigated directly using 
qPCR, FUT4 was included within this study as the enzyme that catalyses its 
synthesis. It was therefore expected that the mRNA levels of FUT4 would be 
significantly higher within the SSEA-1
+
 endometrial epithelial cell fraction. Our 
results were somewhat surprising, showing that there was no difference in expression 
between the SSEA-1
+
 and SSEA-1
-
 fractions taken from the MACS sorted normal 
endometrial samples or endometriosis samples grown in 2D.  In addition, FACS 
sorted samples taken from the normal endometrium showed a 2.5 fold up-regulation 
of FUT4 within the SSEA-1
-
 population when compared to the SSEA-1
-
 cells. This 
could be explained by the fact that the cultured cells had changed their phenotype 
within 2D culture, and therefore expression levels of FUT4 did not represent the true 
levels in vivo. When analysing the results collected from the sorted cells grown in 3D 
culture, which mimics their in vivo microenvironment, we can see that the expression 
levels reverse and FUT4 levels are increased 1.7 fold in the SSEA-1
+
 cells over the 
SSEA-1
-
 cell fraction. Nevertheless, high FUT4 expression within SSEA-1
- 
epithelial 
cells suggests that this gene may have additional or alternative functions. On 
searching the publications, it has been suggested that other FucT genes may be 
involved in the synthesis of SSEA-1 also. Whilst the alternative name given to 
SSEA-1 by the National Center for Biotechnology Information (NCBI, 2012) is 
FUT4, there are a number of publications that suggest that FUT9 is the more 
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dominant enzyme responsible for its synthesis (Nishihara et al, 2003; Nakayama et 
al, 2001). SSEA-1 is regulated throughout brain development and acts as a cell-cell 
recognition molecule within the central nervous system. Nishihara et al compared the 
transcript levels of both FUT9 and FUT4 within developing brain, and found 15-100 
times more FUT9 transcript compared to FUT4. The synthesis of SSEA-1 throughout 
brain development was well correlated with that of FUT9 (Nishihara et al, 2003). 
Nakayama et al also demonstrated that FUT9 has 20-fold stronger activity for the 
synthesis of SSEA-1 over FUT4 within mature granulocytes (Nakayama et al, 2001). 
Sialylated SSEA-1 or Le
x
 (sLe
x
) is a fucosylated structure related to SSEA-1. 
Various studies have shown that multiple FucTs including FUT3, FUT5, FUT6 and 
FUT7 may all be involved in its synthesis (Liu et al, 2008; Nordén et al, 2009). This 
evidence suggests that there may be other important factors in addition to FUT4 
which control the synthesis of SSEA-1. Furthermore, the FUT4 expression in the 
normal endometrium is maximum in the functionalis during the secretory phase of 
the cycle where SSEA-1+ epithelial cells are not present (Ponnanpalam et al, 2008; 
Valentijn et al, 2013), suggesting that FUT4 is not co-expressed with SSEA-1 in 
endometrial epithelial cells. 
 
The results obtained from ERα and PR transcripts between MACS and FACS SSEA-
1 sorted normal endometrial cells, showed obvious differences between the 
expression levels in the two populations, with a clear up-regulation within the SSEA-
1
-
 cells. The expression of these cells are likely to be present in terminally 
differentiated endometrial epithelial cells and more primitive, undifferentiated 
epithelial cells are unlikely to be either steroid hormone responsive and may not 
express the receptors for them. This reached significance for both ERα and PR (WSR 
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test; p=0.0156) within the MACS sorted cells, and indicates a more differentiated 
cell population within the SSEA-1
-
 fraction. This may not have reached the level of 
significance within the FACS sorted samples due to the small number of samples 
used in comparison (n=3), or because contaminating stromal cells within the SSEA-
1
-
 MACS sorted samples were expressing these genes also. Within 3D culture, the 
difference in PR levels was more pronounced, with a 6.7 fold up-regulation of PR 
within the SSEA-1
-
 fraction. Although this was not the case with ERα which 
displayed very similar levels of expression within both fractions grown in 3D culture, 
we know that PR is a marker of a more terminally differentiated cell state than ERα 
and therefore still supports the previous findings (Prianishnikov et al, 1978).   
 
IF staining was used to verify the presence of the protein translated from each of 
these transcripts, within SSEA-1 MACS sorted cells taken from one patient with a 
normal endometrium. The transcription factors OCT4A and NANOG showed nuclear 
staining within a selected number of cells within both SSEA-1
+
 and SSEA-1
- 
cells, 
the correct location for both proteins. More cells stained positively for NANOG than 
OCT4A, which acts as more evidence to suggest that the OCT4 primer pair did not 
exclusively amplify OCT4A mRNA. Interestingly, the OCT4 and NANOG positively 
stained cells showed a different expression pattern to the ESC positive control. 
Within the ESCs, staining for both proteins were seen throughout the nuclei, 
however only part of the nuclei were stained for these proteins within the sorted 
endometrial epithelial cells. ERα, ERβ and telomerase showed nuclear staining in a 
high proportion of cells in both of the sorted populations. For ERβ and telomerase, 
this contradicted what was detected via qPCR, as mRNA levels for both these genes 
were below the level of detection. These results support the claims made by Lehner 
et al and Critchley et al as described previously in chapter 3 (Lehner et al, 2002; 
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Critchley et al, 2002). In contrast, PR and PODXL which were both highly amplified 
using qPCR, showed negative staining for protein across all sorted cells using IF. 
Although it is generally assumed that mRNA and protein levels for a particular gene 
should correlate, analyses in yeast and mammalian cells have shown that this is not 
necessarily the case (Gygi et al, 1999; Anderson et al, 1997). In fact, studies have 
now proven that mRNA levels alone act as unreliable predictors for corresponding 
protein. Protein levels are dependent on a number of factors other than the rate of 
transcription, including nuclear export of the transcript, mRNA localisation, 
transcript stability, translational regulation and protein degradation or in vivo half 
life. Once translated, proteins may also go through post-translational modifications, 
for example glycosylation or phosphorylation, or may undergo proteolytic cleavage 
(Greenbaum et al, 2003; Pradet-Balade et al, 2001). These processes are still not 
sufficiently defined and may account for the discrepancies between the mRNA and 
protein abundances seen within our study. For example, if PR and PODXL proteins 
have short half lives, transcription may occur at high rates due the high demand and 
fast turnover. On the other hand, ERα and telomerase may be stable proteins 
requiring much lower rates of transcription (Greenbaum et al, 2003; Pradet-Balade et 
al, 2001).  
 
5.2 Endometriosis Group 
As endometrial SPCs are thought to be involved in the pathogenesis of 
endometriosis, patients suffering with this disease were also included in our study. 
Similar to the results obtained from the control patients, no significant differences in 
OCT4, NANOG, PODXL and CD133 mRNA levels were found between the two 
human epithelial cell populations MACS sorted on SSEA-1 and grown in 2D, taken 
from endometriosis patients. When placed in 3D culture representing their in vivo 
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environment however, similar to the normal endometrium, these genes were clearly 
up-regulated within the SSEA-1
+
 population when compared to the SSEA-1
-
 cells. In 
addition, these differences in expression appeared to be more exaggerated in those 
with endometriosis than those with normal endometrium, suggesting more stem cell 
activity within these cells from the pathological endometrium. When comparing the 
MACS sorted SSEA-1
+ 
epithelial cell populations directly between the normal and 
endometriosis patients, statistical differences were seen with significant up-
regulation of OCT4 and NANOG within patients with endometriosis. All of these 
results suggest that the SSEA-1
+
 population have heightened stem cell-like activity in 
endometriosis and that they may be involved in the pathogenesis of this condition. If 
a subpopulation of the SSEA-1
+
 epithelial cells are SPCs, then these results would 
support the widely accepted theory that endometrial SPCs are involved in the 
aetiology of this condition (Figueira et al, 2011; Gargett et al, 2010).  
 
In the patients suffering from endometriosis, ERα showed a 1.7 fold higher level of 
expression in the SSEA-1
-
 fraction compared to the SSEA-1
+
 cells. Unlike the 
significant up-regulation of ERα seen previously within the normal SSEA-1- cells, 
this level of expression was not significant for those with endometriosis. In addition, 
when growing these sorted cells in 3D culture that mimics their natural environment, 
an apparent up-regulation of ERα was seen within the SSEA-1+ cells taken from 
patients with endometriosis compared to the paired SSEA-1
-
 cells grown in 3D 
culture and to the SSEA-1
+
 cells from the normal healthy endometrium. Collectively 
these results may be explained by the increase of local oestrogen levels seen within 
patients with endometriosis (Gurates et al, 2003). Endometriosis is recognised as an 
‘oestrogen responsive disorder’, and the growth and maintenance of ectopic 
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endometriotic lesions is dependent on the action of oestrogen. In the endometrium, 
oestrogen acts as a potent mitogen and it is the increased levels of cellular aromatase 
expression in these patients with endometriosis and that leads to greater local 
oestrogen production compared to healthy individuals (Gurates et al, 2003). SSEA-
1
+
 cells are evidently more sensitive and responsive to ERα within patients with 
endometriosis, again substantiating their role in the pathogenesis of endometriosis 
and their existence as endometrial SPCs.  
 
PR showed a significant up-regulation in mRNA levels within the SSEA-1
-
 
population compared to the SSEA-1
+
 cells within patients with endometriosis. This is 
similar to the results obtained from sorted cells taken from the normal endometrium 
grown in both 2D and 3D culture systems, and again seems to indicate that a more 
differentiated cell type may lie within the negative fraction. Although the SSEA-1
+
 
population grown in 3D culture showed higher levels of PR in the endometriosis 
samples compared to the control samples, this level of expression was no different to 
that seen within their SSEA-1
-
 counterpart. In the literature, it is now widely 
accepted that endometriosis is physiologically associated with an element of 
‘progesterone resistance’ and lower overall levels of total PRs, therefore explaining 
the equal levels of expression seen in our results. This phenomenon most probably 
occurs to counteract the anti-proliferative and differentiative effects that progesterone 
has on endometrial cells, thereby contributing to the maintenance of the disease. 
Several mechanisms have been suggested to explain why this resistance process 
occurs. Some claim that there is altered expression of both isoforms of PR (with a 
complete lack of PR-B), their chaperone proteins such as FKBP52 and co-regulators 
including HIC-5/ARA55. Other theories suggest that there is activation of pro-
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inflammatory transcription factors which compete with PR over limited co-
regulators, and also that an increase in free radical production and oxidative stress 
signals may lead to post-translational alteration of PRs (Attia et al, 2000; Brosens et 
al, 2012; Bulun et al, 2006).  
 
Another interesting finding in our study was related to the endometrial epithelial cell 
marker CD9. As a widely accepted marker for endometrial epithelial cells, it was 
expected that the levels of expression for CD9 would be equal in both of the SSEA-1 
sorted populations. This was the case within all samples grown in the 2D culture 
system, as no significant differences in expression levels were found between the two 
populations in the control of endometriosis patients. However, when placed in 3D 
culture, up-regulation of CD9 was evident within the SSEA-1
+
 population compared 
to the SSEA-1
-
 cells; with a 1.5 fold increase within the normal samples and 2.8 fold 
within the patients with endometriosis. CD9 is found to be highly expressed in 
murine and human ESCs and is decreased shortly following differentiation. It is 
likely that CD9 may be under the regulation of the LIF/STAT3 mouse ESC pathway, 
which is required for the self-renewal of undifferentiated mouse ESCs. CD9 is also 
expressed in some ASC populations including HSCs where it is found to be 
important for maintenance of the population and colony formation (Oka et al, 2002; 
Akutsu et al, 2009; Aoyama et al, 1999). If this is the case, then CD9 may have a 
role in maintaining stemness within the endometrium also. This would account for 
the up-regulation seen in the normal SSEA-1
+
 population when grown in an 
environment that represents the stem cell niche, and would account for the greater 
difference seen within patients with endometrioisis which is associated with 
abnormal stem cels. Also this may simply mean greater survival of the epithelial 
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cells in the SSEA-1
+
 population grown in 3D, and it may be possible that the SSEA-
1
-
 epithelial cells do not survive as much in 3D culture. If more stromal cells are 
present in the SSEA-1
- 
population after 2 weeks in 3D, there will be a reduction in 
CD9. We have not tested this theory by also looking at the changes in a gene specific 
to stromal cells such as CD10/CD13 in our study, which may have helped us to 
confirm the reasons for the observed results.  
 
As previously mentioned, in the 2D culture samples, no differences in FUT4 
expression was seen between the SSEA-1
+
 and SSEA-1
-
 populations taken from 
normal or endometriosis patients. It is highly possible that other FucT enzymes may 
be responsible in the synthesis of SSEA-1 also. However, when comparing FUT4 
expression between the SSEA-1
+
 populations isolated from normal and 
endometriosis patients, a significant increase in expression was seen in the cells from 
women with endometriosis. In addition, when placed in 3D culture, expression of 
FUT4 was greater in the SSEA-1
+
 cells of the normal samples and even more so in 
the endometriosis samples when compared to the paired SSEA-1
-
 fraction. This 
provides further evidence to suggest that FUT4 is at least partly associated with the 
synthesis of SSEA-1, and therefore transcript levels were raised within the SSEA-1
+
 
cells grown in 3D culture, where cell proliferation was stimulated. Transcript levels 
were significantly higher in SSEA-1
+
 cells taken from endometriosis patients, 
supporting the hypothesis that SSEA-1
+
 cells are activated in endometriosis and are 
involved in its aetiology. 
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5.3 Limitations of the Study 
Throughout the course of this study, a number of limitations were encountered which 
needed to be considered and acknowledged when interpretations are made for our data. 
One of these limitations was the difficulty of obtaining samples with a good RNA 
quality and yield for use within qPCR. Due to large variations between samples, not all 
biopsies collected would give rise to a good epithelial cell yield suitable for 
MACS/FACS sorting. In addition, cells grown in 3D culture gave rise to small clusters 
of cells producing very little RNA and therefore these samples had to be pooled. This 
is not the ideal sample for study in one hand, but may provide some information that 
can be related to the population of patients included in general. Due to the limited 
number of suitable samples and also the inaccessibility of the FACS machine, the 
number of samples which could be studied within the time available was also limited. 
Ideally, larger sample sizes (especially for FACS and 3D culture analysis) would have 
provided more robust and reliable data. 
 
Another limitation that must be considered is variation between the samples 
themselves. Two different techniques of sample collection, pipelle and full thickness, 
were implemented to collect endometrial biopsies within this study according to the 
patient availability and the kind of surgical procedures they were undergoing. It is 
commonly accepted that pipelle sampling only extracts the cells which are located 
within the functional layer and not those within the basalis, although cells from the 
basal layer may still be taken up through this gentle method of suction.  As it is 
hypothesised that endometrial SPCs are found primarily within the basal layer of the 
endometrium, this raises the question as to whether the results obtained from pipelle 
samples were an accurate representation of the SPC population. Due to the difficulty in 
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obtaining samples however, this could not be avoided but must be considered when 
interpreting the results, especially if the number of pipelle/full thickness samples were 
unevenly distributed between the groups.  
 
Due to the difficulties encountered when trying to obtain suitable samples, biopsies 
were taken from women within all stages of the menstrual cycle. Different cycle stages 
may be associated with different levels of SPC activity, for example an increase in the 
proliferative phase. An uneven distribution of samples taken from different stages of 
the cycle between the normal and endometriosis groups may therefore raise question as 
to the comparability of the results between the groups. Nevertheless, due to the limited 
number of samples, the individual groups could not be subdivided further and analysed 
according to cycle phase. Although it could be argued that as all cells were cultured in 
same in vitro conditions prior to gene analysis, their phenotype would no longer reflect 
their original cycle stage. On the other hand since they do express some ovarian steroid 
receptors, they are likely to have some responsiveness to these hormones in vivo, so 
samples from different stages of the cycle may have SPCs with different activation 
status.  
 
5.4 Future Directions 
In order to encourage scientific advances and improvement within this field, 
suggestions should be made for future work. The obvious need is to increase in the 
number of patients and samples included in this study to confirm the results and 
improve the robustness and reliability of them. Specifically, the study of more FACS 
sorted samples for both normal end endometriosis would fully validate our results, as 
FACS produces more pure populations of cells than MACS. Our study specifically 
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lacked a good number of samples to be grown in 3D Matrigel to provide statistically 
robust data. With more samples, this would have been possible. Ideally, these gland-
like structures too should be grown from FACS sorted cells. This has been attempted 
within our lab but FACS sorting affects the function and viability of these primary 
epithelial cells to a greater degree than MACS sorting, therefore the cells do not seem 
to grow following the FACS sorting. It may be speculated that the FACS sorting 
process damages the cells, for example due to the exposure to high pressures or a 
prolonged time in suspension, therefore affecting their growth and viability. Although 
less efficient, MACS sorting is far gentler and growth of the cells post-sort is not 
affected. With an increase in the sample size included within this study, patients could 
also be subdivided based on the phase of their menstrual cycle, and results could be 
compared according to cycle phase and endometriosis stage to assess whether there 
may be any other correlations. 
 
As previously mentioned, one important property of stem cells which must be 
investigated is their potency. The differentiation capacity of the SSEA-1 sorted 
epithelial cells should be assessed for multi-lineage differentiation potential when 
cultured under the correct conditions, including osteogenic, adipogenic and 
chondrogenic differentiation. Studies to explore in vivo tissue reconstitution of the 
SSEA-1
+ 
population and the responsiveness of the gland-like structures to ovarian 
hormones, progesterone and oestrogen, will provide more evidence to suggest their 
behaviour as endometrial SPCs and further our understanding about this population 
of cells. Once SSEA-1 is firmly established as a marker that selects for a population 
containing the endometrial epithelial SPC population, research needs to be invested 
into identifying a secondary surface marker that co-localises with SSEA-1. It is 
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unlikely that all epithelial cells that express SSEA-1 are SPCS and therefore a 
secondary marker would further select for the subpopulation within the SSEA-1
+
 cells 
of specific endometrial epithelial SPCs.   
 
5.5 Conclusion 
In conclusion, this study has provided data on specific gene expression profile of an 
endometrial epithelial sub-population characterised on the expression of the surface 
marker SSEA-1. The genes that were expressed in this population when compared to 
the SSEA-1
- 
cells have provided evidence to suggest that SSEA-1
+ 
population may 
have a subset of cells with SPCs activity in the human endometrium. Results have 
shown that genes associated with increased stem cell activity and a more 
undifferentiated cell state are  expressed in the SSEA-1
+ 
endometrial epithelial cell 
population when compared to its paired SSEA-1
-
 counterpart, but only when placed in 
the correct conditions that mimic their in vivo micro-environment. This study has 
demonstrated the importance of epithelial cells in particular to be grown in 3D culture 
and the importance of the stem cell niche as a functional unit. We have also shown that 
a subset of these SSEA-1
+
 endometrial epithelial cells may be involved in the 
pathogenesis of endometriosis, observing pronounced expression of genes that may 
induce stem cell activity, oestrogen responsiveness and progesterone resistance in this 
condition. Thus our study provides further evidence to suggest that endometrial SPCs 
are involved in the aetiology of endometriosis.  
 
As not all SSEA-1
+
 endometrial epithelial cells but only a small subset within the 
SSEA-1+ population will be SPCs, it is important to find another surface marker to 
select a pure subpopulation of SPCs to assess whether they possess all known 
functional SPC activity in functional assays such as self-renewal, clonogenicity, 
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differentiation potential and in vivo tissue reconstitution potential. These experiments 
needed to be performed on these cells before any conclusions are made, however, 
growth of primary endometrial epithelial cells are reputed to be challenging and 
usually they do not withstand separation in to single cells. Therefore it will be a 
challenging task to perform these assays in the future studies. Also additional 
investigations to evaluate the responsiveness of these cells to steroid hormones will 
also provide valuable information of the in vivo endometrial regeneration which is 
regulated by these hormones.  
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Appendix II: Specification List for Reagents and Equipment  
Table 18 List of reagent specifications 
 
Reagents Company, City, Country Catalogue Number 
2-propanol Sigma-Aldrich, Dorset, UK I9516 
5x 1st strand buffer Invitrogen, Paisley, UK P/N y02321 
5x DNA loading buffer Bioline, London, UK BIO-37045 
Agarose, Molecular grade Bioline, London, UK BIO-41025 
Anti-SSEA-1(CD15) MicroBeads Miltenyi Biotec, Surrey, UK # 130-090-101 
BD MatrigelTM BD Biosciences, Oxford, UK #354234 
Bovine Serum Albumin (BSA) Sigma-Aldrich, Dorset, UK A9418 
Chlorhexidine gluconate 0.05% (Sterets 
Unisept) 
Medlock Medical Ltd, Oldham, UK AA161/01701 
Chloroform Sigma-Aldrich,  Dorset, UK C2432 
Collegenase  Invitrogen, Paisley, UK #17018029 
Dispase  Invitrogen,  Paisley, UK #17105041 
Dithiothreitol (DTT) (0.1M) Invitrogen, Paisley, UK P/N y00147 
DMEM/F12 Sigma-Aldrich, Dorset, UK D6421 
DNase  Roche, Germany #11284932001 
dNTP Set Bioline, London, UK BIO-39025 
Epithelial growth factor Sigma-Aldrich, Dorset, UK E9644 
Ethanol Sigma-Aldrich, Dorset, UK E7023 
Ethidium bromide Molecular Sigma Biology, Dorset, UK E-7637 
Ethylenediaminetetraacetic acid 
(EDTA) 
Sigma-Aldrich, Dorset, UK 
 
E-5134 
Fetal Bovine Serum (FBS) Biosera, East Sussex, UK FB-1370/100 
Ficoll GE Life sciences,  Little Chalfont, UK 17-1440-02 
FlashGel® DNA Marker (100bp-4kb) Lonza, Slough, UK 50472 
FlashGel
®
 Quantladder (100bp-1.5kb) Lonza, Slough, UK 50475 
FlashGel™ Loading Dye (5x) Lonza, Slough, UK 50463 
Glacial Acetic Acid (17.M) BDH, London & Bristol, UK UN2789 
Glycogen Invitrogen, Paisley, UK 10814-010 
Insulin-transferrin-selenite (ITS) Invitrogen, Paisley, UK #41400-045 
KAPA SYBR FAST qPCR Master Mix 
(2x) 
Kapa BioSystems, Boston, US KK4602 
MgCl2 100mM BDH, Leicestershire, UK  
Mounting Medium for Fluorescence 
with DAPI  
Vector Laboratories, Peterbrough, UK H-1200 
NaCl Sigma-Aldrich, Dorset, UK S5886-500G 
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Table 18 continued List of reagent specifications 
 
Reagents Company, City, Country Catalogue Number 
Neutral Buffered Formalin 
(NBF) 10% 
Sigma-Aldrich, Dorset, UK HT501320-95L 
Normal goat serum (NGS) Biosera, East Sussex, UK GO-605 
Nuclease free water Sigma-Aldrich, Dorset, UK P4417-100TA 
Phosphate Buffered Saline 
(PBS) 
Sigma-Aldrich, Dorset, UK W4502 
Primocin Invitrogen, Paisley, UK P4417-100TA 
Random Hexamers (100ng/μl) Qiagen, West Sussex, UK #ant-pm-2 
RQ1 DNase Buffer Promega, USA AM7020 
RQ1 DNase Stop Soln Promega, USA M198A 
RQ1 DNaseI Promega, USA M1994 
SuperScript III (200U/μl) Invitrogen, Paisley, UK M610A 
Triton 0.2% BDH, Leicestershire, UK 18080-044 
TRIzol® reagent Invitrogen, Paisley, UK 9002-93-1 
Trypsin/EDTA solution Sigma-Aldrich, Dorset, UK 15596-026 
Tween  BDH, Leicestershire, UK #T4049 
 
 
Table 19 List of equipment specifications 
 
Equipment Company, City, Country Catalogue Number 
Carbon steel surgical blade, size 
22 
Swann-Morton, Sheffield, UK 0205 
FACSAriall cell sorter BD Biosciences, Oxford, UK  
FACSCalibur cytometer BD Biosciences, Oxford, UK 342975 
FlashGel dock Lonza, Slough, UK 57025 
Flashgel System Lonza, Slough, UK 57067 
FlashGel™ Camera Lonza, Slough, UK 57040 
Hand-held homogenisor Qiagen, West Sussex, UK 9001272 
Molecular Imager® Gel DocTM 
XR 
Bio-Rad, Hertfordshire, UK #170- 8270 
Nanodrop software NanoDrop Technologies, 
Wilmington, USA 
ND-8000 
NanoDropTM 1000 
Spectrophotometer 
NanoDrop Technologies, 
Wilmington, USA 
ND-1000 
Rotor-Gene 3000 centrifugal 
real-time cycler 
Corbett Research, Sydney, 
Australia  
 
Teales Vulsellum uterine forceps Phoenix Surgical Instruments 
Ltd, Hertfordshire, UK 
PH725903 
163 
 
Table 20 List of consumable product specifications 
 
Equipment Company, City, Country Catalogue Number 
8-well chamber slides BDH Chemicals, Leicestershire, 
UK 
734-2050 
22x40mm coverslip WBFM, London, UK GP1001125004 
24-well tissue culture plate Biowhittaker, Suffolk, UK DMEM-F12 
Cell strainer, 40μm Miltenyi Biotec, Surrey, UK # 130-090-101 
Centrifuge tube, 15ml Appleton Woods, Birmingham, 
UK 
SC060 
Chamber removal tool BDH chemicals, Leicestershire, 
UK 
734-0089 
Falcon tube, 50ml BD Biosciences, Oxford, UK 358206 
MACS separation column Miltenyi Biotec, Surrey, UK MS columns, #130-042-201 
Microcentrifuge tube, 1.5ml Sarstedt Ltd, Leicester, UK 72699 
Parafilm Pechiney Plastic Packaging, 
Menasha 
WI 54952 
Pastette, 1ml StarLab, Milton Keynes, UK #E1414-0110 
PCR tube, 0.2ml (flat cap) StarLab, Milton Keynes, UK I1402-8100 
Petri dish, 100mm BDH chemical, Leicestershire, 
UK 
734-2321 
Tissue cultureT75cm2 flasks BD Biosciences, 
Oxford/Swindon/Plymouth, UK 
137787 
Two-tier 16+1 2.2% agarose 
cassette 
Lonza, Slough, UK 57032 
Universal tube, 100ml Sarstedt Ltd, Leicester, UK  
Universal tube, 30ml Sarstedt Ltd, Leicester, UK  
Universal tube, 50ml Sarstedt Ltd, Leicester, UK  
Yellow pre-filter, 30μl Miltenyi Biotec, Surrey, UK #130-041-407 
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Appendix VII: Nanodrop Results 
Table 21 Nanodrop results for normal endometrial samples 
 
 ng/μl 260/280 
N51 + 117.5 1.69 
N51 - 939.3 1.89 
N54 + 214.1 1.74 
N54 - 580.9 1.81 
N58 + 64.9 1.66 
N58 - 746.1 1.85 
N52 + 53.2 1.5 
N52 - 715.8 1.82 
N53 + 66.7 1.8 
N53 - 1089.8 1.94 
N55 + 126.8 1.66 
N55 - 744.2 1.92 
N49 + 124.6 1.7 
N49 - 407.0 1.91 
N59 + 276.4 1.79 
N59 - 758.4 1.85 
N77 + 54.5 1.77 
N77 - 107.8 1.76 
N85 +  7.4 1.62 
N85 - 119.3 1.82 
N86 + 21.1 1.77 
N86 - 62.0  1.90  
N95+ 31.7 2.45 
N95 - 217.6 1.91 
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Table 22 Nanodrop results for endometriosis endometrial samples 
 
 
 ng/μl 260/280 
E36 + 157.4 1.79 
E36 - 602.4 1.81 
E40 + 45.3 1.80 
E40 - 352.6 1.90 
E41 + 249.6 1.77 
E41 - 652.5 1.90 
E42 + 86.3 1.78 
E42 - 412.1 1.91 
E43 + 403.0 1.87 
E43 - 469.5 1.82 
E44 + 6.6 1.68 
E44 - 4000.4 1.95 
E46 + 618.8 1.90 
E46 - 50.2 1.82 
E48 + 291.0 1.80 
E48 - 736.2 1.90 
 
 
 
Table 23 Nanodrop results for organoid samples 
 
 
 ng/μl 260/280 
Pooled N54, N55, N57 + 339.5 1.86 
Pooled N54, N55, N57 - 196.2 1.84 
Pooled E42, E43, E44 + 778.5 1.89 
Pooled E42, E43, E44 - 362.9 1.85 
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Appendix VIII: Standard Curves 
For all qPCR serial dilution experiments: 1x = red, 1/5x= blue, 1/25x= purple, 1/125x= 
orange, 1/625x=green, 1/3125x= yellow, NTC= pink.  
 
Threshold for all qPCR graphs set at 0.07. 
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Quantification Analysis:  
 
 
 
Melt Analysis:  
 
 
 
 
 
 
 
 
 
 
180 
 
Primer efficiency =0.74 
 
 
 
OCT4 Standard Curve 
 
Quantification Analysis:  
 
 
 
Melt Analysis:  
 
 
 
181 
 
Primer efficiency =0.95 
 
 
 
SOX2 Standard Curve 
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Primer Efficiency= 0.76 
 
 
 
CD9 Standard Curve 
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Primer Efficiency= 1.26 
 
 
 
YWHAZ Standard Curve 
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Primer Efficiency= 1.14 
 
 
 
YWHAZ Standard Curve 
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Primer Efficiency= 0.86 
 
 
 
CD133 Standard Curve 
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Primer Efficiency= 1.01  
 
 
 
 
ERα Standard Curve 
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Primer Efficiency= 1.01 
 
 
 
ERα Standard Curve 
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Primer Efficiency= 1.08 
 
 
 
ERα Standard Curve 
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Primer Efficiency= 1.02 
 
 
